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Resumo 
 
A proteína Tau esta envolvida no assembly e na estabilização dos microtúbulos (MT) contribuindo para a 
normal função destes. Alterações na quantidade e na estrutura da Tau, como é o caso da hiperfosforilação, 
desencadeiam a libertação da Tau que medeia a estabilização dos MT, levando ao sequestro desta, 
formando agregados. Este processo pode estar envolvido em muitas doenças neurodegenerativas 
referidas como Tauopatias, como e o caso da doença de Alzheimer. Uma das características mais 
evidentes da doença de Alzheimer é a formação de tranças neurofibrilares compostas por deposições 
intracelulares de agregados de Tau hiperfosforilados. Contudo, o mecanismo que está na origem da 
transformação de Tau solúvel em agregados insolúveis, bem como o mecanismo envolvido na propagação 
dos agregados, continua sem explicação. Um modelo in vitro que reproduza as principais características 
envolvidas na doença pode ser uma útil ferramenta para estudar as causas e consequências da agregação 
da Tau.  
No presente estudo, foram optimizados dois modelos celulares, um em que foram utilizadas células QBI e 
outro em que foram utilizados neurónios corticais de rato. As culturas foram expostas a fibrilas pré-
agregadas sinteticamente produzidas, a partir de Tau recombinante (K18P301L), que podem recrutar Tau 
endógena solúvel transformando-a em agregados insolúveis. A vantagem destes modelos é o rápido 
processo de agregação, uma vez que com o uso das fibrilas o passo limitante, a nucleação, é ultrapassado, 
e a transformação de Tau de forma monomérica em agregados é acelerada. Foi provado que em culturas 
neuronais primarias as fibrilas pré-agregadas são absorvidas espontaneamente, não sendo necessário o 
uso de nenhum reagente de entrega, o que leva a crer que este processo é mediado por endocitose. A 
indução de agregação endógena através das fibrilas de Tau sintéticas é um processo dependente do 
tempo de exposição, uma vez que foi detectado um aumento de agregação com um aumento do tempo 
de exposição às fibrilas, o que representa um ponto de suporte na hipótese de propagação patológica da 
Tau. No presente estudo foi também descrito que o processo de agregação desencadeado no modelo de 
agregação neuronal hTauP301L, não é um processo neurotóxico. 
Os modelos descritos neste estudo foram utilizados como uma plataforma para testar compostos que têm 
como finalidade diminuir os níveis de agregação da Tau. Neste estudo, foi também testado um inibidor de 
Hsp90 que demonstrou um evidente efeito na diminuição da Tau solúvel e insolúvel. 
Utilizando os modelos celulares apresentados, no presente estudo foi testado o processo da agregação da 
Tau em células. Foram desenvolvidos dois ensaios, um ensaio de BRET e um ensaio de Venus split 
complementation para estudar o processo de agregação da Tau no QBI seeding model. 
Resumidamente, o estudo apresentado tem por objectivo estabelecer uma relevante plataforma que 
pode ser utilizada para o estudo da patologia da Tau, bem como identificar futuras terapias com base na 
proteína Tau. 
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Abstract 
 
Tau protein promotes assembly and stabilization of microtubules (MT), which contributes to proper 
neuronal function. Alterations in the amount and structure of Tau protein, as hyperphosphorylation, 
results in detachment from MTs and sequestration into aggregates leading to a loss of Tau-mediated MT 
stabilization. This process is present in some neurodegenerative disorders referred as Tauopathies, such 
as Alzheimer Disease (AD). One of the major hallmarks of the AD is the formation of neurofibrillary tangles 
(NFTs) composed of intracellular deposition of hyperphosphorylated Tau aggregates. 
However the mechanisms causal of the conversion of soluble Tau in insoluble Tau aggregates, as well the 
propagation of Tau aggregates remains inconclusive. An in vitro system recapitulating the characteristics 
of this disease would provide a useful tool to study the causes and consequences of Tau aggregation.  
In this study, we optimized two cellular models, in QBI cells and in rat cortical neurons, wherein synthetic 
pre-aggregated fibrils made from recombinant protein (K18P301L) introduced in cell cultures can recruit 
soluble endogenous Tau into insoluble fibrillar aggregates. The advantage of these models is a faster 
aggregation process once the fibrils can overstep the rate limiting nucleation and accelerate the 
transformation of monomeric Tau into aggregates. We found that pre-aggregated fibrils are 
spontaneously taken up by primary cortical neurons and that this does not require any delivery reagent. 
This could mean that the uptake of this material is mediated by endocytosis. The induction of endogenous 
aggregation by synthetic Tau fibrils is a time-dependent process, since we observed an increase in Tau 
aggregation with increasing exposure time to fibrils, supporting the hypothesis of propagation of 
pathological Tau. We also found that the aggregation process triggered in the hTauP301L neuronal 
aggregation model is not a neurotoxic process to rat cortical neurons.  
The models described in this study were used as a platform to test compounds that could potentially 
decrease the levels of Tau aggregation. In this study an HSP90 inhibitor was test that demonstrated 
evident effects in decreased of soluble and insoluble Tau. 
The cellular models present here, were also used to study Tau aggregation process in life cells. In this 
study, we developed two assays, a BRET assay and a Venus split complementation assay to study Tau 
aggregation process in the QBI seeding model.  
In summary, we have developed and optimized a platform which can be used to study the pathogenesis of 
Tauopathies, and indentify new Tau-based therapies.  
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Dementia is a group of symptoms and signs manifested by difficulties in memory, disturbances in 
language, and changes in behavior. In most cases, aging is the major risk factor to dementia. Meta-analysis 
studies done in developed countries have established dementia prevalence at around 1-5% at age 65 
years, which doubles every 4 years to reach about 30% at 80 years (Ritchie & Lovestone, 2002). However, 
dementia is not only a burden on the people affected and their carries but also a heavy financial burden to 
the society. Knapp and colleagues estimated that in UK, 224 000 of the 461 000 people with cognitive 
impairment live in institutions costing 8.2 billion dollars every year (Ferri et al., 2005). More than 25 
million people in the world today are affected by dementia, most suffering from Alzheimer’s disease (AD) 
(Qiu, Kivipelto, & Strauss, 2009). 
 
1.1. Alzheimer’s disease 
 
1.1.1. Epidemiology  
 
Population aging is a worldwide universal phenomenon, 
being that worldwide aged population will increase from 
59% to 71%. The incidence of AD is strongly associated with 
increasing age. In both developed and developing countries, 
AD has had tremendous impact on the affected individuals, 
caregivers, and society (Qiu et al., 2009). 
According to the world Alzheimer’s report, there were 35.6 
million people living with dementia in 2010, increasing to 
115.4 million by 2050 being 50%-70% AD cases (Jackson, 
2009). The prevalence of the disease in Europe, in people 
older than 65 is 4.4%, whereas in the US people older than 
70 shows a prevalence of AD around 9.7%. The age-specific 
prevalence of AD almost doubles every 4 years  after age 65 (Qiu et al., 2009; Ritchie & Lovestone, 2002) 
[Figure 1]. 
 
 
1.1.2. Risks and protects factors 
 
Various risks factors have been found to be associated with AD, like cerebrovascular disease, diabetes, 
hypertension, obesity, dyslipidemia and metabolic syndrome driving to pathogenic processes that result in 
Figure 1 - Age-specific prevalence of Alzheimer’s 
disease (per 100 population) across continents and 
countries (Qiu et al., 2009). 
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decreasing the vascular integrity of the blood-brain-barrier (BBB). The BBB breakdown causes increase in 
neuronal oxidation, adipokines and cytokines, that results in β-amyloid deposition and abnormal 
phosphorylation of Tau, thereby contributing to the formation of NFTs and amyloid plaques (Reitz C, 
Brayne C, 2011) and an increased AD risk, and memory impairment. The APOEε4  allele of the 
apolipoprotein E (APOE) gene is reported as the strongest risk factor for the development of AD and is 
believed to be involved in β-amyloid (Aβ) aggregation (Qiu et al., 2009). 
On the other hand, some evidences suggests that dietary intake of vitamin B12, folate, antioxidants, such 
vitamin C and E, unsaturated fatty acids and moderate alcohol intake, especially wine, could reduce the 
risk of AD (Blennow, Leon, & Zetterberg, 2006). In addition, there are psychosocial factors that could be 
protective to AD, such as high educational attainment, mentally stimulating activities, social activity, 
enriched social network and physical activity (Qiu et al., 2009). 
 
 
1.1.3. Alterations in Alzheimer’s disease brains and symptoms 
 
Neurodegeneration in AD is estimated to start 20-30 years before clinical onset. During this phase, the 
hallmarks of disease, senile plaques and NFTs, begin to increase, and when a certain threshold is reached, 
the first symptoms arise (Blennow et al., 2006). However, the disease often initially manifests as a 
syndrome termed mild cognitive impairment (MCI), which is usually 
characterized by a memory complaint and impairments on formal 
testing, however with intact general cognition, preserved daily 
activities and absence of overt dementia (Morris et al., 2001; 
Petersen & Morris, 2005). MCI is an aetiological heterogeneous 
entity because many patients with MCI have Alzheimer’s disease, 
whereas others patients have a form of MCI as part of the normal 
ageing process. MCI has been suggested to constitute a transitional 
stage between normal ageing and AD (Blennow et al., 2006; Petersen 
& Morris, 2005) [Figure 2].   
Decrease in white matter density and synaptic loss are associated 
with aging (Yankner, Lu, & Loerch, 2008) whereas, synaptic loss is 
one of AD hallmarks  and associated with cognitive impairment.  
However, in some brain areas affected in early AD does not 
necessary resut in a significative loss of neurons or neuronal 
connectivity, accoording to some results (Scheff & Price, 2006; 
Figure 2 - Progression of neuropathology 
in aging and Alzheimer’s disease. Shown 
are the neuroanatomical distribution of 
amyloid plaques and NFTs (Adapted 
Yankner et al., 2008). 
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Scheffa, Pricea, Schmitt, Scheff, & Mufson, 2011). Nevertheless different populations of neurons in brain 
regions critical for memory, learning and cognitive performance is associated with abnormalities in AD. 
There is a damage in various circuits, as basal forebrain cholinergic system, hippocampus and cortex.  
Neurodegeneration in this regions fundamentally results from NFT, related to cytoskeletal abnormalities, 
and the presence of ß-amyloid peptide, that is involved in cognitive decline present in this disease (J. C. 
Morris et al., 2001; Siegel, Albers, Brady, & Ph, 2006). 
The clinical manifestations of symptomatic AD include increasing difficulties with memory and with other 
cognitive functions, such as impaired judgment, decision making and orientation. The patients could be 
presented instrumental signs that include aphasia, apraxia, and agnosia. In later stages, these individuals 
become profoundly demented and usually die of undercurrent illnesses (Blennow et al., 2006; Siegel et al., 
2006)  
 
 
1.1.4. Genetics of Alzheimer’s disease 
 
According to age of onset, two major types of AD are usually distinguished: early-onset form (EOAD) and 
late-onset form (LOAD). However, an important part of the EOAD form occurs in a familial history context, 
whereas most forms of LOAD are considered sporadic, without associated with family history (Lambert & 
Amouyel, 2011; Tanzi & Bertram, 2001). 
The EOAD form is often caused by autosomal dominants mutations which accounts for only about 2% - 5% 
of all Alzheimer patients (Reitz, Brayne, 2011). This form occurs before the age of 65, and is associated 
with mutations in genes encoding amyloid precursor protein (APP), presenilin-1 (PSEN1) and  presenilin-2 
(PSEN2) (Lambert & Amouyel, 2011). The APP gene is localized on chromosome 21. APP is a membrane 
protein cleaved by secretases. This cleavage of APP by secretases leads to both non-amyloidogenic 
processing, and the amyloidogenic processing, with production of Aß. APP mutations result in privileged 
processing of APP through the amyloidegenic pathway (Ballard et al., 2011; Yankner et al., 2008). 
Mutations in highly homologous PSEN1 and PSEN2 account for most cases of familial disease. The PSEN1 
gene is on chromosome 14, and the PSEN2 gene is on chromosome 1 and both have homologous 
functions (Nussbaum & Ellis, 2003). They are both components of γ-secretase, which involved in APP 
processing into Aß. Familial mutations in this genes can alter production of Aß1-42 which form plaques 
more readily than Aß1-40 (Ballard et al., 2011; Blennow et al., 2006).  
The genes involved in LOAD, increase disease risk and are not inherited in a Mendelian fashion (Reitz, 
Brayne, & Mayeux, 2011). LOAD occurs in patients over 65 years old, and it is the most common form of 
AD. The association of APOEε4 allele with AD was reported in 1993 (Corder et al., 1993). Meta-analyses 
studies shows that this allele increases the risk of disease by three times in heterozygotes and by 15 times 
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in homozygotes, and with each allele copy lowering the age at onset by almost 10 years (Blennow et al., 
2006). APOE is involved in cholesterol transport, and different isoforms have differing transport 
efficiencies. APOE also binds Aß in an isoform-specific manner, and these alleles are associated with 
increased amyloid burden and cholinergic dysfunction (Ballard et al., 2011).  
However, there are other candidates genes involved in AD although being their contribution probably 
minor. Genome-wide associated studies identified news genes involved with LOAD form of disease, these 
being CLU (clusterin), PICALM (phosphatidylinositol-binding clathrin assembly protein), CR1 (complement 
receptor 1), BIN1 (bridging integrator 1), ABCA7 ( ATP-binding cassette transporter), MS4A cluster 
(membrane-spanning 4-domains subfamily A), CD2AP ( CD2-associated protein), CD33  (sialic acid binding 
immunoglobulin-like lectin) and EPHA1 (ephrin receptor A1) (Morgan, 2011). Tau haplotype (H1C) is 
associated with AD, and affects expression levels of Tau splice isoforms (Ballard et al., 2011). 
Unfortunately, the successful identification of novel AD genes in the sporadic form of AD has several 
obstacles. 
 
 
1.1.5. Hallmarks of AD 
 
In AD there are two major pathological hallmarks, the accumulation of extracellular insoluble deposits of 
an Aß and intracellular tangles consisting of hyperphosphorylated Tau protein. 
 
1.1.5.1. ß-amyloid protein  
 
APP is a type I transmembrane protein and its processing arises through alternative splicing resulting in 
three different isoforms, APP695, APP751 and APP770 (containing  695,751 and 770 amino acids, 
respectively) (Y. Zhang, Thompson, Zhang, & Xu, 2011). The isoforms APP751 and APP770 are expressed in 
most tissues and contain a 56 amino acid Kunitz Protease Inhibitor (KPI) domain within their extracellular 
regions (Menéndez-González, Pérez-Pinera, Martínez-Rivera, Calatayud, & Blázquez Menes, 2005). Protein 
levels of KPI-containing APP isoforms are elevated in AD brain, and this is associated with increased Aß 
deposition.  
APP role has been suggested to be involved in neurite outgrowth and synaptogenesis, neuronal protein 
trafficking along the axon, transmembrane signal transduction, cell adhesion, calcium metabolism and 
among others (Zheng & Koo, 2006). 
APP can be sequentially cleaved by groups of enzymes or enzyme complexes termed α, ß, γ-secretases 
(LaFerla, Green, & Oddo, 2007). APP can undergo proteolytic processing by one of two pathways 
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depending on the kind of enzymes and proteolysis sites the non-amyloidogenic pathway or the 
amyloidogenic pathway (Haass, Kaether, 
Thinakaran, & Sisodia, 2012).  
In the non-amyloidogenic pathway, APP is 
cleaved approximately in the middle of the Aß 
region between residues Lys16 and Leu17 by 
the α-secretase enzyme (Esch et al., 1990). The 
APP cleveage by α-secretase releases a large 
soluble ectodomain of APP called sAPPα, which 
is secreted into extracellular medium. This 
domain has an important role in neuronal 
plasticity/survival, protection against 
excitotoxicity, and also regulation of neuronal 
stem cell proliferation (Furukawa et al., 1996; 
Mattson, 1997). Subsequently, the resulting 
domain, 83-amino-acid C terminal fragment (C83), is retained in the membrane and cleaved by γ-
secretase, producing a short fragment termed p3, which apparently is pathologically irrelevant (LaFerla et 
al., 2007) [Figure 3].  
Amyloidogenic pathway is an alternative cleavage pathway for APP which leads to Aß generation (LaFerla 
et al., 2007). The first step of this pathway is the APP cleavage by BACE1, the major ß-secretase (Zhang et 
al., 2011). This cut results in release of sAPPß into extracellular space, and leaves the 99-amino-acid from 
C-terminal stub (known as C99) within the membrane. The subsequent cleavage of this fragment by γ-
secretase releases an intact Aß peptide and p83 fragment. Most of full-length Aß peptide produced is 40 
residues in length (Aß40), whereas a small proportion (approximately 10%) is the 42 residue variant (Aß42). 
This variant is more hydrophobic and more aggregation prone and believed to be the toxic building block 
of Aß oligomers, which affect memory and cell survival (Haass & Selkoe, 2007; LaFerla et al., 2007)[Figure 
3]. In addition to secretases, caspases can directly cleave APP at position Asp664. Studies suggests that 
caspase cleavage of APP seems to be crucial for Aß-mediated neurotoxicity, since a mutation in this 
position in transgenic mice negated the synapse, electrophysiology, and behavioral abnormalities, even 
though Aß plaques were still abundant in the brain (Galvan et al., 2006; Zhang et al., 2011).  
Figure 3 – Proteolytic processing of APP within the anti-
amyloidogenic and amyloidogenic pathways (Adapted from 
Thinakaran & Koo, 2008) 
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The majority of Aß is secreted out of the cell, and this peptide can also be generated in subcellular 
compartments within the cell, such endoplasmic reticulum, Golgi complex, and in the 
endosome/lysosome. In addition, 
extracellular Aß can be internalized for 
cell degradation. The intracellular 
existence of Aß implies that it may 
accumulate within neurons and 
contribute to AD. Aß internalization can 
lead to intracellular aggregates, which 
can lead to vesicular membrane 
disruption, contributing therefore to the 
pathological effect (Zhang et al., 2011). 
Gradual changes in the levels of Aß toxic species in the brain are thought to initiate the amyloid cascade. 
The ratio between Aß42/ Aß40 can be increased by mutations in the three genes involved in familial form of 
the AD. The relative increase of Aß42 enhances oligomer formation, which causes subtle and then 
increasingly severe and permanent changes of synaptic function, inhibiting hippocampal LTP (Yankner et 
al., 2008) [Figure 4].  
Recent studies suggest that Aß oligomers can also alter glutamatergic neurotransmission by promoting 
the endocytosis of NMDA and AMPA receptors (Snyder et al., 2005). Consequently, local inflammatory 
responses arise, due to the activation of microglia and astrocytes [Figure 4]. Over time, these events result 
in altered neuronal ionic homeostasis, oxidative stress, and formation of NFTs that are induced by altered 
kinase and phosphatase activities that causes additional defects, as for example alterations in axonal 
transport. This cascade culminates in extensive synaptic/neuronal dysfunction and cell death, leading to 
progressive dementia (Blennow et al., 2006; Haass & Selkoe, 2007; Hardy & Selkoe, 2002). Overproduction 
of Aß results in a neurodegenerative cascade, leading to synaptic dysfunction, formation of intraneuronal 
fibrillary tangles and eventually neuronal loss in affected areas of the brain (Selkoe, 1998). 
 
 
1.1.5.2. Tau protein  
 
i. Structure and function of the normal Tau  
 
Microtubule-associated protein Tau was identified as a microtubule-assembly factor in the mid of 1970s 
(Weingarten, Lockwood, Hwo, & Kirschner, 1975). This protein is associated with promotion of the 
Figure 4 - Representative of neurodegenerative mechanism in Alzheimer’s 
disease (Yankner et al., 2008).  
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assembly and stabilization microtubules, which contributes to the proper function of neurons (Kolarova, 
García-Sierra, Bartos, Ricny, & Ripova, 2012).  
Tau belongs to the microtubule-associated proteins (MAPs) family, and it is highly conserved and 
exclusively found in higher eukaryotes. This protein is mainly expressed in neurons, but also present in 
oligodendrocytes, and its primary role, by interacting with microtubules, is to stabilize neuronal 
cytoskeleton (Neve, Harris, Kosik, Kurnit, & Donlon, 1986). The Human Tau gene is over 100kb and is 
located on the long arm of chromosome 17 at the position 17q21 and contains 16 exons. The exons 1, 4, 5, 
7, 9, 11, 12 and 13 are constitutive exons. Exons 2, 3, and 10 undergo alternative splicing and they are 
present in the adult brain. In the central nervous system, alternative splicing in these exons results in 
appearance of six Tau isoforms that are differentially expressed during development of the brain 
(Sergeant, Delacourte, & Buée, 2005). These isoforms range from 352 to 441 amino acids with an 
apparent molecular weight between 
60 and 74 KDa (Martin, Latypova, & 
Terro, 2011) [Figure 5].  
The human Tau protein is a product 
of a single RNA transcript and is 
subdivided into four regions: 1) An N-
terminal region that can associate 
with the cell membrane and regulate 
the spacing between microtubules; 2) 
A Proline-rich region including many 
phosphorylation sites that can bind 
to SH3 domains of other proteins, 
including tyrosine kinase Fyn; 3) The 
microtubule-binding domain (MBD), 
a region responsible for Tau binding 
to microtubules; 4) C-terminal region (Martin et al., 2011; Sergeant et al., 2005). Depending on 
developmentally controlled alternative mRNA splicing, the repeat domain of Tau can consist of either 
three or four repeats of 31 of 32 residues each. The 4R variant contains R1=Q244-K274, R2=V275-S3015, 
R3=V306-Q336 and R4=V337-N368. The 3R variant lacks repeat R2 that is encoded by exon 10. The form 
without two inserts in N-terminal region called 0N, with one N-terminal insert, 1N, and with two N-
terminal inserts 2N. This gives rise to six combinations corresponding to the six Tau isoforms: 2N4R; 1N4R; 
2N3R; 0N4R; 1N3R; and 0N3R (Martin et al., 2011; Sergeant et al., 2005) [Figure 5]. However, only the 
0N3R Tau isoform is present during fetal stages, while the isoforms with one or two N-terminal inserts and 
3R or 4R are expressed during adulthood (Martin et al., 2011; Sergeant et al., 2005). 
Figure 5 - Schematic representation of transcription and alternative splicing of 
Tau protein. The diagram indicates the structure of chromosome 17 and the six 
different Tau isoforms after the Tau transcription, with their length and 
molecular weight (J.-Z. Wang & Liu, 2008). 
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The major biological function of Tau is to promote microtubule assembly and maintain the stability of the 
previously formed microtubules, which are essential for the axonal transport of neurons. There is a 
gradient of Tau along the axon in which highest levels are closest to the synapses (Dixit, Ross, Goldman, & 
Holzbaur, 2008; Mandell & Banker, 1996). Tau also promotes stabilization of microtubules, because it 
binds to tubulin and is incorporated into the growing microtubules as an integral structure (Kar, Fan, 
Smith, Goedert, & Amos, 2003;Wang & Liu, 2008). Additionally, the interaction of Tau with diverse 
structural and functional proteins suggests that Tau may play crucial roles not only in normal architecture 
but also in signal transduction of the neurons. Most recently it was discovered that Tau, by the 
phosphorylation, also participates in the regulation of the cell viability (Li et al., 2007).  
 
ii. Tau post-translational modifications 
 
During normal development, Tau protein undergoes various post-translational modifications, since the 
regulation of Tau takes place predominantly through these. Tau phosphorylation is the most common 
post-translational modification, however others post-translational modifications as glycosylation, 
glycation, poly-isomerization, truncation, nitration, polyamination, ubiquitination, oxidation and 
aggregation have an important role in maintenance of the structure and conformational state of Tau.  
 
Tau phosphorylation  
Tau is a phosphoprotein containing normally 1–3 moles of phosphate per mole of Tau protein. Tau can be 
phosphorylated at three amino-acid types, serine (S), threonine (T), and tyrosine (Y). 17% of the Tau 
protein is constituted by these three amino acids (Martin et al., 2011;Wang & Liu, 2008). This protein has 
among 85 putative phosphorylation sites, of which 45 are serines (53% of the phosphorylation sites on 
Tau), 35 are threonines (41%) and 5 are tyrosines (6%). A decrease or increase in Tau phosphorylation 
alters its affinity for microtubules which results in neuronal cytoskeleton modifications (Martin et al., 
2011). For example, Tau phosphorylation at residues S262, S293, S324 and S356 has been shown to 
decrease Tau binding microtubules (Dickey et al., 2007) and decrease the flexibility of the protein 
(Himmelstein, Ward, Lancia, Patterson, & Binder, 2012). 
The expression and phosphorylation of Tau seem also developmentally regulated. In embryonic and early 
postnatal stages, a single isoform of Tau is expressed with high levels of phosphorylation, while in the 
brain of the healthy adult, a much lower level of Tau phosphorylation has been detected with a 
simultaneous appearance of various Tau isoforms (Goedert et al., 1993).  
The phosphorylation is regulated by various kinases and phosphatases, and an unbalance between these 
enzymes families can result in Tau hyperphosphorylation. According to the motif-specificity, Tau kinases 
can be divided into three major groups: proline-directed protein kinsases (PDPKs); non-proline directed 
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protein kinases (NPDPKs) and protein kinases specific for tyrosines. Glycogen synthase kinase - 3ß (GSK3ß), 
cyclin-dependent kinase 5 (CDK5), and mitogen-activated protein kinases (MAPKs) are protein kinases 
PDPKs (Sergeant et al., 2008). The NPDPKs include calcium- and calmodulin-dependent protein kinase II 
(CAMKII), PKA, protein kinase C, among others (Wang & Liu, 2008). Alterations in the expression and/or 
activity of Tau kinases such as PDPKs have been reported in the brains of AD patients, suggesting that one 
or several of them could be involved in the Tau hyperphosphorylation observed in the AD brain (Martin et 
al., 2011). 
On the other hand, Tau hyperphosphorylation could be a result from phosphatase inhibition. Protein 
phosphatase-2A (PP2A) accounts for more than 70% of cellular phosphatase activity and is implicated in 
the regulation of Tau phosphorylation levels (Liu, Grundke-Iqbal, Iqbal, & Gong, 2005; Virshup & 
Shenolikar, 2009). 
 
Tau glycation  
Glycation refers to non-enzymatic linkage of sugars to the amino side chain of polypeptide. This reaction 
leads to subsequent oxidation and finally formation of heterogeneous products called advanced glycation 
end products (AGE). Twelve sites of glycation were found on Tau protein, seven of them are located in 
MBD regions. Glycation might contribute to block Tau degradation and, therefore, promote its 
pathological accumulation and neuronal cell death (Martin et al., 2011; Yan et al., 1994). 
 
Tau glycosylation 
Glycosylation is the covalent reaction that links oligosaccharides to the side chain of proteins with help of 
glycosyltransferase. According to the nature of glycosidic bond, they are classified into O- and N-linked 
glycosylation: O-glycosylation results from the attachment of sugar to the hydroxyl group of serine or 
threonine in the proximity of a proline residue; N-glycosylation results from the attachment of sugar to 
the amine radical of asparagine side chain of proteins (Gong, Liu, Grundke-Iqbal, & Iqbal, 2005; Robertson, 
Moya, & Breen, 2004). Tau protein contains 11 putative O-glycosylation sites. Tau glycosylation decreases 
its phosphorylation by PKA, CDK5 and GSK3ß. Particularly O-glycosylation achieved by the engraftment of 
N-acetyl-glucosamine (O-GlcNAcylation) has been shown to reduce phosphorylated Tau in rat cortex and 
hippocampus. This may result from competition between phosphorylation and glycosylation for the same 
sites on Tau protein (Yu et al., 2008; Yuzwa et al., 2008).  
 
Tau prolyl-isomerization 
Prolyl-isomerization is the reaction that allows the rearrangement to disulfide bonds in proteins. This 
reaction modifies the conformation of the target proteins from cis to trans conformation. Prolyl-
isomerization of Tau is achieved by peptidyl-prolyl cis-trans isomerase Pin1 (Martin et al., 2011). 
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Alteration in Tau conformation from cis to trans leads to a shift of the peptide chain in space, making 
them more accessible to phosphatases, and Tau prolyl-isomerization by Pin1 to trans conformation 
facilitates its dephosphorylation by PP2A (Bulbarelli, Lonati, Cazzaniga, Gregori, & Masserini, 2009). Pin1 
knock down showed increased Tau aggregation and to influence APP processing towards a decrease in Aß 
production. This evidences that Pin1 activity interference, either by inhibiton or reduction, misfolded Tau 
protein presence, or even blocking of Tau protein accessibility might lead to Tau pathology (Martin et al., 
2011).  
 
Tau truncation 
Truncated Tau proteins are conformationally different from normal healthy Tau. Caspase-3 proteolytic 
cleveage of Tau leads to the formation of fragments with 46 kDa and 20 kDa, and calpain-mediated Tau 
cleavage generates a product of 17 kDa (Martin et al., 2011). Tau truncated by caspase at Asp421 exerts 
stronger microtubule-assembly potency than the full-length Tau molecule a determined by in vitro assays 
(Gamblin et al., 2003). The truncated fragment can cause cell apoptosis (Wang & Liu, 2008). Compared 
with full-length Tau proteins, the cleavage products of Tau are reportedly more prone to form aggregates 
(Yin & Kuret, 2006).  
 
Tau nitration 
Nitration is the addition of nitrogen dioxide on tyrosine of an organic molecule, and this occurs at 4 sites 
in Tau: Tyr18, Try29, Tyr197 and Tyr394 (Wang & Liu, 2008). Nitration has been associated with AD since 
the nitration of Tyr29 was found only in severely affected AD brains, but not in normal aged brains 
(Reynolds et al., 2006). Nitration was proposed to decrease Tau ability to promote tubulin assembly 
leading to Tau oligomerization (Martin et al., 2011). 
 
Tau polyamination 
The polyamination reaction occurs by transglutaminases involving a glutamine as acyl donor group, and a 
lysine as acyl acceptor donor. Tau polyamination reaction is observed on the protein before NFT 
formation, so it might be involved in NFT formation process (Singer, Zainelli, Norlund, Lee, & Muma, 2002). 
 
Tau ubiquitination 
Ubiquitination is the specific binding of one or more molecules, of a small protein, ubiquitin, to proteins, 
that will signal proteins for their degradation in the cytosol by the ubiquitin-proteasome-system (UPS) 
(Martin et al., 2011). This system participates in defending against misfolded proteins and provides an 
affective protein quality control system that is essential for cellular survival and functions (Wang & Liu, 
2008). Tau normally exists as an unfolded protein and it is degraded in vitro by the core (20S) of 
13 
 
proteasome that functions in an ubiquitin-independent manner (David et al., 2002). Proteins after 
associated with ubiquitin, which is a 76-amino acid protein, are degraded by ubiquitin-proteasome 
machinery in an ATP-dependent manner (Avila, Lucas, Perez, & Hernandez, 2004). The ubiquitin ligase for 
Tau is identified as the C terminus of Hsp70-interacting protein (CHIP). This protein works in combination 
with heat shock proteins, that are induced by the stress derived of the accumulation of misfolded proteins. 
The combination of the shock proteins and CHIP is important to regulate Tau degradation; a reduction of 
CHIP levels in AD brains was discovered. The levels of heat shock protein 90 (Hsp90) correlate inversely 
with levels of soluble Tau and Tau oligomers (Morris, Maeda, Vossel, & Mucke, 2011). As such, in non-
pathological conditions Tau has been shown to be ubiquitinated and proteolytically processed by UPS.  
 
 
1.1.6. Interaction between Aß and Tau in pathological condition  
 
Aβ and Tau, the two main proteins involved in AD, exhibit separate toxicity in this disease. There are 
however some evidences in vitro and in vivo of the possibility of interaction between these two proteins. 
Amyloid oligomers are proposed to precede, and eventually trigger intracellular Tauopathy, likely by 
increasing phosphorylation of Tau protein.  
The first evidence supporting that Aβ drives Tau pathology was given by Götz, et al. They have shown that 
Aβ42 fibrils injected into the brains of P301L mutant Tau transgenic mice caused a significant increased in 
NFTs formation (Götz, Chen, et al., 2001).  
Hurtado et al. developed an AD mouse model generated by crossing PS19 and PDAPP transgenic mice that 
developed Aß and Tau pathology. They showed that Aβ protein accelerated NFT formation, and enhanced 
Tau amyloidosis, however the reverse was not found in this model, meaning that Tau protein did not have 
the same effect on Aβ pathology (Hurtado et al., 2010). There is also evidence of induction of neuronal 
Tau hyperphosphorylation by Aβ oligomers in rat mature hippocampal cultures (De Felice et al., 2011). 
Another piece of evidence for the hypothesis of Aβ and Tau interaction is the fact that Tau can mediate Aβ 
toxicity. It was found that neurons from Tau knockout mice are protected from Aβ-induced cell death in 
cell culture (Ittner et al., 2010; Roberson et al., 2007). Tau reduction also prevents Aβ induction defects in 
axonal transport of mitochondria which may link the Tau hypothesis to other ones, axonal transport 
impairment hypothesis, according to which Tau induces failure of axonal transport (Stamer, Vogel, Thies, 
Mandelkow, & Mandelkow, 2002) and also with oxidative stress hypothesis, which suggest that 
mitochondria are functionally impaired which will result in production of reactive oxidative species 
(Combadière, Raoul, Guillonneau, & Sennlaub, 2013). 
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Although scientific research has given an increase in knowledge about the roles of Tau and its interaction 
with Aβ pathology, many questions about the scaffolding partners for Tau in its interaction with Aβ are 
still unanswered.  
 
 
1.2. Pathogenic mechanism associated with Tau 
 
Intraneuronal aggregation of abnormally phosphorylated Tau in NFTs constitutes a major 
neuropathological hallmark of Tauopathies such as AD. Tau related diseases are considered as a group of 
more than twenty heterogeneous dementias and movement disorders that are neuropathologically 
characterized by intracellular accumulations of abnormal filaments formed by the microtubule-associated 
protein Tau (Lee, Goedert, & Trojanowski, 2001). These disorders are the consequence of abnormal Tau 
phosphorylation, abnormal levels of Tau, abnormal Tau splicing or mutations in Tau gene. Aggregates 
consist almost exclusively of Tau protein, albeit as different isoforms in different diseases, that is either 
Tau 3R or Tau 4R or as a variable mixture (Jaworski, Kügler, & Van Leuven, 2010). However these diseases 
can be differentiated by the subcellular compartments containing pathologic Tau filaments associated 
with disease and with specific brain regions affected (Himmelstein et al., 2012) . Table 1 shows the various 
examples of these diseases.  
 
Table 1 - Summarization of the most frequent disorders associated with Tau pathology. 
Tau-related disorder Characteristics References 
 
Corticobasal degeneration 
- Cognitive disturbance, like aphasia, apraxia and 
moderate dementia; 
- Frontoparietal atrophy and glial neuronal Tau inclusions; 
- Presence of hyperphosphorylated Tau. 
(Avila et al., 2004; Jung et al., 
2012; Lee et al., 2001; Rana, 
Ansari, & Siddiqui, 2012) 
 
Down’s Syndrome 
- Trisomy in chromosome 21; 
- Results in the defective growth and maturation of the 
brain, producing a cognitive impairment and dementia; 
- Tau is hyperphosphorylated similar to AD; 
(Avila et al., 2004; Lee et al., 
2001) 
 
Frontotemporal dementia 
with parkinsonism linked to 
chromosome 17 (FTDP-17) 
- Fontotemporal atrophy, with neuronal loss, gliosis and 
cortical spongiform changes in the lobes; 
- Tau inclusions in neurons and glial cells; 
- Tau missense mutations occur preferentially in the 
microtubule binding region; 
- Mutations affect the binding of Tau to other proteins that 
bind to that region of Tau. 
(Jesus Avila et al., 2004; (Grover 
et al., 1999; Hutton, 2001; Lee et 
al., 2001) 
 
Pick’s diesease 
- Dementia, with disturbances in language and behavior; 
- Associated with frontal lobe atrophy; 
- Presence of cytoplasmic Tau inclusions in neurons of the 
frontal lobe. 
(Jesus Avila et al., 2004; V. M. Lee 
et al., 2001; Rossor, 2001; 
Takeda, Kishimoto, & Yokota, 
2012) 
 
Progressive supranuclear 
- Characterized by supranuclear palsy, prominent postural 
instability; 
- Tau inclusions are found in neuronal and glial cells, with 
astrocytes and oligodendrocytes affected; 
(Jesus Avila et al., 2004; de 
Yébenes, Sarasa, Daniel, & Lees, 
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palsy - Tau polymorphism may be a risk factor. 1995; Dickson, Rademakers, & 
Hutton, 2007; V. M. Lee et al., 
2001) 
 
Other Tauopathies 
- Tauopathies involving hyperphosphorylated Tau, 
including parkinsonism with dementia, myotonic dys-
trophy, prion diseases with tangles, among others. 
(Buée, Bussière, Buée-Scherrer, 
Delacourte, & Hof, 2000; Ingram 
& Spillantini, 2002) 
 
The causes of Tau aggregation in sporadic Tauopathies are not completely understood. However, 
abnormalities in post-translational modifications seem to alter the proprieties of Tau (Avila, Santa-María, 
Pérez, Hernández, & Moreno, 2006). 
 
 
1.2.1. Tau aggregation and spreading evidences  
 
In many neurodegenerative disorders involved with protein aggregation, like AD, the end-stage 
aggregated structure is considered a fibrillar amyloid deposit, normally with approximately 10 nm. These 
deposits are characterized by positive staining with Congo red or thioflavin T and by the signature parallel 
ß-sheet structure diffraction patterns observed by X-ray fiber diffraction analysis. However, not all protein 
aggregates in central nervous system (CNS) are of the amyloid fibrillar type. Tau protein forms non 
structured aggregates intracellularly in neuronal tissues. Although it is a controversial question, because 
there are some authors that classify Tau protein inclusions as an intracellular amyloid configuration 
(Pedersen & Heegaard, 2013). The amyloid fibrillation process features characteristic kinetics. Fibril 
growth is normally preceded by a long lag phase, where monomers try out intermolecular interactions 
until, a stable oligomeric assembly or a nucleus is formed. After formation of nuclei, fibrils show 
exponential growth until the reaction reaches an equilibrium phase, where the rate of fibril growth equals 
that of shrinkage. The addition of pre-aggregated forms eliminates the lag phase, the process known as 
“seeded” polymerization (S.-J. Lee, Desplats, Sigurdson, Tsigelny, & Masliah, 2010) [Figure 6]. During the 
course of seeded polymerization, subtle conformational variations in aggregates are propagated through 
structural conversion of newly added monomers. Fibrillar aggregation typical of amyloid-forming proteins 
depends on a regular, stacked ß-sheet structure which may be generated through partially unfolded 
intermediates (Pedersen & Heegaard, 2013). 
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The biological process defined as an aggregation process is that association of two or more non-native 
protein molecules, that is largely driven by hydrophobic forces and primarily results in the formation of 
amorphous structures (Hartl & Hayer-Hartl, 2009).  
Studies demonstrated that the principal post-translational modifications 
involved in aggregation are phosphorylation, truncation, glycation, and 
nitration (Cho & Johnson, 2004; Horiguchi et al., 2003; Ledesma, Medina, & 
Avila, 1996). Different studies in cells have shown that phosphorylation of 
Tau influence Tau on least two levels, in Tau-microtubule interactions and 
Tau-Tau interactions. Phosphorylation tends to decrease the binding of Tau 
to microtubules of KXGS motifs and Ser214 having particularly pronounced 
effects (Illenberger et al., 1998). The result is a decrease in microtubule 
stability, but more significantly an increase in the cytosolic pool of Tau, that 
could  contribute to aggregation into paired helical filaments PHFs 
(Mandelkow, Von Bergen, Biernat, & Mandelkow, 2007). 
The progressive accumulation of specific protein aggregates is a defining 
feature of many neurodegenerative diseases, including AD. Tau proteins 
aggregate into intraneuronal filamentous inclusions. In AD, these filaments 
are called PFH, and their constitutive proteins are referred to as PFH-Tau 
proteins (Buée et al., 2000) [Figure 7]. The aggregation of Tau is based on 
short hexapeptide motifs 275VQIINK280 and 306VQIVKY311 at the beginning of 
R2 and R3. These aggregation motifs have a partially hydrophobic 
character and predisposed to interact with cross-β structure, contributing 
to the core of PHFs (Illenberger et al., 1998).  
Figure 6 - Scheme of amyloidogenic protein aggregation process. The black trace represents the non-induced amyloidogenesis 
process, whereas the red trace represents the induced amyloidogenic process. This process is dependent of nucleation, and 
after this phenomenon there is a rapid elongation phase (SJ, Lee, HS, Lim, E, Masliah, HJ, 2011). 
Figure 7- Scheme of the aggregation 
process in Tau pathology (Martin et 
al., 2011). 
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This conformation is  also characteristic of prion strains, recently  reported to other disease-linked 
proteins, such as Tau, Aß and α-synuclein (Frost, Ollesch, Wille, & Diamond, 2009). Prion disease belongs 
to the group of protein misfolding neurodegenerative diseases, and these misfolded  
proteins are highly ordered in filaments inclusions with core region of cross-ß-conformation (Goedert, 
Clavaguera, & Tolnay, 2010). However, the diseases related with prions have an important difference with 
other diseases related with misfolded proteins, since prions disease can be transmitted between 
individuals across species and can spread from the point of infection, often from peripheral tissue to the 
central nervous system (Collinge & Clarke, 2007). Prionic diseases are a fatal neurodegenerative disorders, 
associated with conversion of cellular prionic protein into a scrapie prionic protein. An abnormal 
conformation state that is predisposed to form an amyloid deposits in brain tissue leading to dementia 
(Vingtdeux, Sergeant, & Buée, 2012). The propagation of prion aggregates can occur at a relatively fast 
and efficient step, this propagation is accelerated when aggregates break into smaller seeds that serve to 
recruit additional monomers (Lee et al., 2010). Nevertheless studies observed that the formation of Tau 
and α-synuclein inclusions as a function of age has shown to develop in a stereotypical manner in 
particular brain regions from where they appear to spread (Michel Goedert et al., 2010). Recent research, 
tissue culture studies and in vivo studies describing the induction of protein misfolding and spreading 
between cells, have shown most convincingly that common neurodegenerative disorders can be driven by 
cell non-autonomous mechanisms (Clavaguera et al., 2009; Kane et al., 2000; Ren et al., 2009), it can be 
seen in table 2 for Aβ, Tau, and α-synuclein.   
 
Table 2 - Evidences for speeding of non-protein aggregates in the central nervous system (adapted from (Jellinger & Popescu, 
2012) 
Inoculum Host Propagation effect References 
Aβ    
Brain homogenates from AD 
or APP transgenic mice 
APP transgenic  mice 
(intracerebral  injection) 
Aβ deposition at injection site 
and in adjacent brain 
structures 
(Eisele et al., 2009; 
Meyer-Luehmann et al., 
2006) 
Tau    
Tau fibrils Cultured neuronal cells 
Endocytic uptake of exogenous 
Tau fibrils and induction of 
cytoplasmic endogenous 
Tau proteins. Cell-to-cell 
transmission of Tau taken up 
by cultured cells 
(Frost, Jacks, & 
Diamond, 2009; Guo & 
Lee, 2011; Nonaka, 
Watanabe, Iwatsubo, & 
Hasegawa, 2010) 
Brain extracts from Tau 
transgenic mice 
Transgenic mice expressing 
human wild-type (WT) Tau 
(intracerebral injection) 
Spreading of Tau from site of 
injection to other brain 
structures 
(Clavaguera et al., 
2010; Piao et al., 2001) 
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Diamond and colleagues demonstrated by the first time that in cell cultures there is an uptake of Tau 
fibrils added to culture medium and the fibrils can induced fibrillation of cytoplasmatic Tau (Frost, Jacks, et 
al., 2009).  
There is also another study that reported the evidence of cell-to-cell transference of Tau proteins, the 
Calvaguera et al. study, where they reported the propagation of Tau in transgenic mice.  Brain extracts of 
transgenic mice (P301S) with filamentous of Tau, were injected into the hippocampus and cerebral cortex 
of ALZ17, a transgenic line over expressing the WT Tau protein. Tau deposition was found not only within 
the injection sites but also in neighboring brain regions, being severely diminished with the increasing 
distance from the injection site, and they could see an increase in brain lesions over time (Clavaguera et 
al., 2009). This could mean however that this was due to perfusion of the injected material throughout the 
brain. 
Different research in this area have demonstrated that Tau aggregates can propagate a misfolded state 
inside cells and provided also an experimental system where molecular mechanisms underlying the 
intracellular transfer of inclusions can be identified (Goedert et al., 2010). The major fundamental 
question in this subject is what is the mechanism of the prion-like spreading of Tau pathology to selective 
regions of the brain. One of the possibilities would be that the selectivity of the propagation could follow 
neuronal circuits through synaptic transmission. That could be possible by exossomes, small specialized 
membranous vesicles that can be secreted by many cell types including neuronal cells. Synaptic activity 
could enhance exossomal production and secretion by neurons (Lachenal et al., 2011). Another 
explanation could be the existence of tunneling nanotubes, the fine membrane channels that have 
recently been described in mammalian cells for communication between cells, but also for cell-cell 
propagation of misfolded prion protein (Vingtdeux et al., 2012). Zhang et al. described that tunneling 
nanotubes are induced in rodent hippocampal neurons and astrocytes by oxidative stress. We also know 
that cell-to-cell connection and communication of intracellular organelles or Aβ could be triggeredd by 
α-Synuclein    
Aggregate-producing 
neuronal cell cultures 
 
Neuronal cells 
Endocytic uptake of α-Syn 
aggregates 
(Desplats et al., 2009) 
Introduction of α-Syn 
aggregates by preformed 
fibrils generated from 
truncated recombinant 
human WT α- Syn 
Primary hippocampal neurons 
Adsorptive-mediated 
endocytosis promoting soluble 
α-Syn into insoluble PD-like 
Lew bodies and Lewy neurites 
(Volpicelli-daley et al., 
2012) 
Transgenic mice 
overexpressing human α- 
Syn 
Mouse neuronal progenitor cells 
grafted into mouse brains 
Interneuronal transmission of 
human α-Syn 
(Desplats et al., 2009) 
Brains of patients with 
Parkinson disease 
Foetal stem cells grafted into the 
brains of 
patients with Parkinson disease 
Interneuronal transmission of 
Lewy inclusions 
(Luk et al., 2009; 
Mendez et al., 2008; 
Ren et al., 2009) 
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cellular stress. The stressed cells, like degenerating neurons, would connect via tunneling nanotubes to 
closely surrounding or connected neurons to delivery pathogenic proteins. So, these mechanisms of cell-
to-cell communication under stress conditions could contribute to neurodegenerative diseases and 
explain the spreading that occurs in neurons in these cases (Wang, Cui, Sun, & Zhang, 2011). It also has 
been shown that Tau protein aggregates present in extracellular space can be internalized into cells 
through endocytosis. Internalized Tau aggregates showed partial co-localization with dextran, a feature 
indicative of involvement of the endocytic pathway (Frost, Jacks, et al., 2009). Aggregates are packaged 
into endocytic vesicles, and therefore, require another mechanisms by which they can gain access to the 
cytosol (Frost, Jacks, et al., 2009). 
 
 
1.2.2. Pathological species associated with Tau aggregation 
 
Over the last few years, researchers have been describing toxic species of Tau protein associated with AD. 
One of the hallmarks of AD is the accumulation of NFTs in the brain; however these are not the exclusive 
pathological form of Tau protein that exist in AD patients brain. Thus, some investigators have shifted 
their focus to not just to study NFTs, but also to study pre-filament Tau species such as Tau oligomers and 
hyperphosphorylated Tau monomers. 
 
 
1.2.2.1. Tau oligomers  
 
Non-fibrillar Tau aggregates of different sizes have been reported by various research groups, as possibly 
the most toxic and pathologically significant forms of Tau aggregates (Francisco, 2007; Lasagna-Reeves et 
al., 2011). This toxic species is considered to be intermediates between soluble Tau monomers and 
insoluble Tau filaments.  
Tau oligomer is the term used to describe any complex of two or more Tau molecules in a multimeric 
structure. They can be formed both by hyperphosphorylated and by non-phosphorylated Tau proteins and 
they have been shown to be both soluble (they are made up a small number of Tau proteins), or insoluble 
(when they include a large number of Tau molecules) (Cowan, Quraishe, & Mudher, 2012). 
Different research groups identified small soluble oligomers of approximately 140 and 170 kDa in brain 
homogenates of P301L transgenic mice (mice used as Tauopathy model with Frontotemporal lobar 
degeneration (FTLD) mutation) (Berger et al., 2007; Sahara et al., 2007). The oligomers detected by Berger 
and colleagues appeared at early stages of disease when memory deficits were evident in the absence of 
tangle formation or neuronal loss. The majority of the 140 kDa oligomers appeared to be soluble and did 
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not contain hyperphosphorylated Tau proteins, however the 170 kDa oligomers detected in sarkosyl-
insoluble fraction showed Tau proteins hyperphosphorylated at the residues (Ser202/Thr205, Ser396 and 
Ser422) (Berger et al., 2007).The effect of this kind of Tau oligomers on physiological processes has been 
investigated. The oligomers that Lasagna-Reves and colleagues developed, have been shown to be toxic in 
vitro (Lasagna-Reeves, Castillo-Carranza, Guerrero-Muoz, Jackson, & Kayed, 2010) and in vivo (Lasagna-
Reeves et al., 2011). When SH-SY5Y cells were treated with soluble oligomers, these oligomers cause 
significantly more cell death than Tau monomers or filaments (Flach et al., 2012; Lasagna-Reeves et al., 
2010) 
The large insoluble oligomers were first described by Takashima group and were described as granular Tau 
oligomers. This species consist of an average of 40 molecules of Tau, which normal size of 180 kDa and 
with 20 nm of diameter. The granular oligomers were identified in early Braak stages in human brain and 
can also form from recombinant non-phosphorylated Tau in vitro. However, with advance of pathology by 
Braak stages the levels of granular oligomers decreased, when tangle formation is higher, meaning that 
they could be pre-tangle structures (Maeda et al., 2006).  
Concluding, the precise composition and pathological significance of oligomers has yet to be fully 
understood.  
 
 
1.2.2.2.  NFTs 
 
NFTs are toxic species characterized by intraneuronal accumulation of fibrillar material named PHF. This 
term was introduced by Kidd in 1963 to describe filaments in AD neurons (Kidd, 1963). PHF is produced by 
a double helical stack of morphological units, each with a C-shaped cross-section displaying three domains. 
By electron microscopy, PHF was determined to have between 8 nm and 20 nm of width with a cross-over 
spacing of 80nm (Crowther, 1991).  A higher level of organization will be the arrangement of protofibrils 
within a PHF. Their number of interactions is currently unknown, but there are several constrains for 
possible arrangements. One of them described that the mass per-length of the PHF core, determined by 
scanning transmission electron microscopy is about 60-70 KDa/nm, equivalent to approximately 3.5-4.5 
repeat domain molecules per nm (von Bergen et al., 2006). 
With aging, NFT spread from the transentorhinal cortex to the hippocampal formation. Neuropathological 
as well biochemical studies show that Tau spreads progressively, invariably from the transetorhinal cortex 
to the whole neocortex, along the cortical-cortical connections (Vingtdeux et al., 2012). However, recently 
Braak and Del Tredici describe locus coeruleus as the initiating region of NFT formation (Braak & Del 
Tredici, 2011) 
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Hyman and colleagues defined 3 majorly stages of NFTs, pre-tangle phospho-Tau aggregates, 
intraneuronal NFTs, and extraneuronal NFTs. Pre-tangles showed granular cytoplasmatic phospho-Tau 
staining, with a detectable nucleus and the normal cell morphology. This was observed especially with 
phosphor-Tau antibodies, which recognize phosphorylation at T231, S262 and T153.  
Intraneuronal NFTs includes aggregated filamentous structures within cytoplasm and the cell nucleus, but 
these often eccentric or pyknotic. These fibrillar structures of Tau were most preeminently stained with 
phosphorylation dependent antibodies that recognize T175, T185 and S262, S356, S422, S46, S214.  
Extraneuronal aggregates show extracellular phospho-Tau filaments, but these are not related with to the 
neuronal soma or nucleus. This prominent filamentous form of Tau is most significantly recognized by 
antibodies recognizing the phosphorylation at S199, S202, S205, S214 and T212. However, in intracellular 
and extracellular NFT there are common phosphorylated sites S396 and S404 (Augustinack, Schneider, 
Mandelkow, & Hyman, 2002; Lu, 2005). 
 
 
1.2.3. The role of Tau in pathogenic mechanism  
 
In pre-clinical stages of AD, Tau pathology is distributed in the hippocampal formation and temporal 
cortex. However, Braak et al, described that when Tau pathology is found in other brains areas, it is 
constantly along stereotyped, sequential pathways categorized into six stages according to the brain 
regions successively affected. Initially there is the occurrence of pretangles in axons and dendrites of 
noradregenic cells. After this, pretangles also appear in non-thalamic brainstem nuclei with diffuse cortical 
projections. Stage I, includes the formation of pre-tangles in the cerebral cortex. The cell-to-cell 
propagation of abnormal Tau molecules could utilize synaptic contacts between subcortical terminal 
axons and pyramidal cells of the transentorhinal region. The pathological process progresses to 
mesocortical areas of the media temporal lobe and to neocortical high-order association areas as been 
defined by Braak as NFT stage II, III, and IV. The stage V-VI is defines as when NFT reach secondary and 
primary fields of the neocortex. This hypothesis suggested by Braak propose that the spreading process is 
a process likely transmitted through cortical-cortical connections, in an organized manner and not 
randomly and most likely not by diffusion ( Braak & Braak, 1991; Braak & Del Tredici, 2011). 
Evidence that Tau mutations and hyperphosphorylation can affect microtubule binding proposes that 
impairment of microtubule function and axonal transport contributes to neurodegeneration in AD 
(Brunden, Trojanowski, & Lee, 2009a). Alterations in the expression and the activity of Tau kinases such as 
GSK3ß, CDK5, and CK1 have been reported in the brains of AD, suggesting that one or several of them 
could be involved in the Tau hyperphosphorylation (Chung, 2009). GSK3ß phosphorylates Tau at T231 
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residue, which makes the C-terminus of Tau an easier substrate for hyperphosphorylation, promoting NFT 
formation (Martin et al., 2011)[Figure 8].  
On the other hand, PP2A activity is reduced in 50% of AD brains, and in in vitro studies, incubation of Tau 
aggregates with this phosphatase restores Tau binding to microtubules to a level similar to that of controls. 
The endogenous inhibitors of PP2A, I1
PP2A and I2
PP2A , have 
been shown to be increased by 20% in neurons of AD 
brains and to co-localize with PP2A and 
hyperphosphorylated Tau (Chen, Li, Grundke-Iqbal, & Iqbal, 
2008).  
Recent results may indicate that abnormal phosphorylation 
is a key event that triggers the pathological aggregation of 
Tau in AD (Mondragón-Rodríguez et al., 2008). The other 
post-translational modification, glycation, is also involved 
in promotion of Tau polymerization and stabilization of 
aggregated Tau proteins, but it does not induce Tau 
aggregation by itself (Martin et al., 2011). Nitration may 
also promote aggregation, since Tau nitration at Y29 was found in AD brains, is proposed that nitration 
decreases Tau ability to promote tubulin assembly leading to Tau oligomerization (Martin et al., 2011). 
Another post-translational event that may facilitate Tau aggregation is proteolytic cleavage, as it seems 
that both calpain and caspases, can act on Tau producing fragments that may have an increase propensity 
to aggregate (Brunden et al., 2009a) 
It is possible that changes in protein kinase and/or phosphatase activities could enhance Tau 
phosphorylation resulting in loss-of-function (LOF) and/or gain-of-function (GOF) toxicities. However, 
additional post-translational modifications may also contribute to Tau dysfunction (Alonso, Zaidi, 
Grundke-Iqbal, & Iqbal, 1994).  
The hypothesis that Tau LOF contributes to neuronal dysfunction shows that disease phenotype were 
caused by loss of Tau function due to hyperphosphorylation and sequestration of soluble Tau (Zhang et al., 
2005). In other words, neurodegeneration is due to the loss of Tau caused either by a decrease in Tau 
microtubule binding capabilities or by a decrease of the available pool of Tau protein as a result of 
aggregation and/or phosphorylation (Dawson et al., 2010). However, there are data that contradict the 
viewpoint that Tau LOF contributes to neurodegeneration, because some recent studies demonstrated 
that loss of Tau function is an unlikely cause of neurodegeneration and neuronal dysfunction. Studies 
suggest that the complete depletion of Tau in Tau knockout mice does not cause premature mortality or 
major abnormal deficits (Dawson et al., 2010; Yuan, Kumar, Peterhoff, Duff, & Nixon, 2008). Based in 
electrophysiological recordings in acute hippocampal slices, Tau knockout mice and WT controls have 
Figure 8 - Representation of the hyperphosphorylation 
of Tau that occurs in in AD (Mazanetz & Fischer, 2007). 
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similar NMDA/AMPA receptors currents, synaptic transmission strength and short-term as well long-term 
synaptic plasticity (Roberson et al., 2011; Shipton et al., 2011).  
On the other hand, the other hypothesis predicts that misfolded and aggregated Tau protein causes a gain 
of toxic function by delaying normal axonal processes. This argument is supported by in vitro experiments 
demonstrating that mutations in Tau gene either decrease the binding of Tau to microtubules or increase 
aggregation of the mutant Tau proteins (Barghorn et al., 2000;Gamblin et al., 2000). It is hypothesized that 
the decreased ability of mutated Tau to bind to microtubules would allow for more free Tau and therefore 
increase Tau aggregation (Dawson et al., 2010). Being mutated Tau more prone to aggregate, and taking 
in account that Tau aggregates are toxic, it is possible to affirm that Tau gains a toxic function.  
 
 
1.2.4. Cellular model to study the effect of Tau in Tauopathies  
 
Cellular models have also been used in AD research. Guo et al. established a cellular system that robustly 
develops NFT-like Tau aggregate which provides mechanistic insights into NFT pathogenesis. The induction 
of formation of intracellular aggregates in this model is different to the models described previous since (i) 
intracellular aggregates are morphologically different to the previous studies; (ii) the intracellular 
aggregates exhibits a diversity of morphologies, which probably represent different stages of aggregation 
similar to Tau tangles detected in Tauopathies; (iii) Use of protein delivery reagent to augment 
introduction of performed fibrils into cells provides better efficiency of Tau performed fibrils entry as 
compared to previous studies.  
In this study, Tau aggregation could be rapidly induced within hours after the introduction of small 
quantities of misfolded Tau preformed fibrils and result in accumulation of large amounts of insoluble Tau 
fibrils.  
In summary, the authors of this paper established a reproducible and robust, cellular model of Tau 
aggregation in which the key features of Tauopathies are present. This model is a potential system for the 
identifying therapeutic strategies against Tauopathies.  
Until now the present model to test aggregation in vitro proposed by Guo and the colleagues seems to be 
the best model to test the Tau aggregation.  
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1.2.5. Animal models to study the effect of Tau in Tauopathies 
 
Several approaches have been adopted in an attempt to model Tauopathies in vertebrates, to elucidate 
their pathogenic mechanisms and to investigate potential therapeutics interventions.  Transgenic animals 
for genomic human Tau, as well as mice carrying  cDNAs encoding either the largest or the smallest CNS 
isoform of human Tau have been generated (Avila et al., 2004).  
In the field of the Tauopathies, there are several models of transgenic mice expressing either the longest 
Tau isoform (4R-Tau), that may favor fiber formation, or the shortest one (3R-Tau) (Buée et al., 2000). The 
first transgenic mice to be published that carried cDNA encoding the largest human brain Tau isoform 
showed low levels of overexpression. The transgenic human Tau protein was present in nerve cell bodies, 
axons and dendrites (Götz et al., 1995).  Two studies reported the generation of transgenic mice 
expressing mutant human Tau containing the P301L mutation that is located in the tubulin-binding 
domain, and that reduces the affinity of Tau microtubules (Götz, Tolnay, et al., 2001; Lewis et al., 2000). 
These transgenic mouse lines expressing human MAPT with a proline to leucine mutation at amino acid 
301 (P301L) recapitulate aspects of familial FTLD (Orr, Pitstick, Canine, Ashe, & Carlson, 2012), having 
developed NFTs mainly in the spinal cord, and like the previous transgenic models,  some 
neuropathological symptoms encouragingly reminiscent of the human disease  (Götz et al., 2001). In this 
model it was verified that extensive axonal and myelin degeneration also occurred in peripheral nerves, 
and that neuronal loss is similar of what occurs in FTLD and the other Tauopathies. This model also shows 
a behavioral deficit (Lewis et al., 2000).  
A significant body of data demonstrates that a  large excess of normal or mutant human Tau can promote 
some of the cellular changes observed in Tauopathies, however that this may also be insufficient for the 
formation of the mature neurofibrillary aggregates observed in the human disease (Avila et al., 2004). 
Thus, transgenic mice models of Tauopathies exhibit similarities which the pathological mechanisms 
involved in AD, especially in regard to the aberrant intracellular targeting of Tau proteins (Buée et al., 
2000).   
 
 
1.3. Tau focused AD treatments 
 
Treatments of various aspects of Tau biology are under intense investigation. Therapies targeting Tau 
phosphorylation, aggregation and microtubule stabilizers are already in clinical trials for people with MCI, 
AD and different Tauopathies. However more research in this field is necessary.  
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Figure 9 - Structures of the compounds that inhibits Tau 
kinases (Brunden et al., 2009). 
 
Tau phosphorylation inhibitors  
Normal Tau is phosphorylated at many residues, and the extent of this phosphorylation is considerably 
increased in the brains of patients with AD (Matsuo et 
al., 1994). Inhibiting Tau hyperphosphorylation requires 
an understanding of the specific enzymes that are 
involved in these modifications (Brunden, Trojanowski, 
& Lee, 2009). Numerous Tau kinases have been 
implicated in AD pathogenesis, but the most widely 
studied are GSK-3ß, CDK5, MARK and MAPK.  
There is indeed substantial evidence to suggest that 
CDK5 and GSK-3ß are relevant kinases in Tauopathies. 
Interestingly, both kinases have been implicated in the 
upregulation of Aß synthesis, so inhibition of these 
kinases leads to a decrease in Aß levels (Phiel, Wilson, Lee, & Klein, 2003). Recent animal studies 
demonstrated that Lithium, a potent inhibitor of GSK-3ß, decreases levels of phosphorylated Tau and the 
expression of this kinase in the cortex and hippocampus, suggests that GSK-3ß is one of the key targets for 
future disease-modifying therapies for AD (Mendes et al., 2009; Selenica et al., 2007). MARK1, another 
important kinase present in Tau fibrils in AD brain, could be a most promising candidate to reduce Tau 
hyperphosphorylation. Cells that overexpress this kinases showed increased Tau phosphorylation, and 
enhanced neurotoxicity (Brunden et al., 2009).  
Although kinase inhibitors have been used successfully in oncology, it remains to be determined whether 
these molecules can be usefully administrated on a chronic basis for the treatment of Tauopathies.  
 
Tau aggregation inhibitors  
Conversion of soluble Tau into oligomeric and fibrillar species could result in Tau GOF and LOF toxicities. 
Inhibiting Tau assembly into multimeric structures might therefore prevent the formation of toxic species 
and increase the levels of monomeric Tau, which could contribute to the microtubules stabilization 
(Brunden et al., 2009).  
The first compound that was reported to inhibit Tau interactions was the phenothiazine methylene blue, 
which was shown to alter the structure of existing PHFs that were isolated from the brains of patients with 
AD (Wischik, Edwards, Lai, Roth, & Harrington, 1996) [Figure 10]. Results of the Phase II data presented at 
2008 international conference on Alzheimer suggests that this compound had a positive therapeutic effect, 
even though larger Phase III studies are required (Brunden et al., 2009). 
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Another dye-like molecule, N744, has also been 
identified as an inhibitor of full-length Tau 
fibrillation and, like methylene blue, this 
compound could disaggregate existing filaments 
(Chirita, Necula, & Kuret, 2004).  
However, many of the drugs that block 
aggregation of the Tau also block the 
pathological aggregation of others proteins 
under cell free conditions, including Aß and α-
synuclein, suggesting that therapies might be of 
benefit in diverse disorders correlated with protein aggregation (Morris et al., 2011). 
Many of the existing Tau assembly inhibitors have chemical or biological properties that will probably 
make them unsuitable for the generation of reactive species that increase the potential for off-target 
effects (Brunden et al., 2009). Therefore preferred compounds are likely to be those that prevent the 
initial stages of Tau-Tau interaction, so they lead to an increase of Tau monomers and not uncharacterized 
intermediate multimeric structures, which could have a biological activity (Brunden, Trojanowski, & Lee, 
2008) [Figure 13].  
 
Enhancing intracellular Tau degradation  
There are two pathways involved in degradation of the misfolded cytosolic proteins, UPS and 
macroautophagy. There is evidence that both of these 
systems may be affected in AD brain and, although 
normal Tau has not been shown to use these systems, 
there are reports which suggests that 
hyperphosphorylated and misfolded Tau can undergo 
degradation through both of these pathways (Keller, 
Hanni, & Markesbery, 2000; Nixon et al., 2005).  
The ubiquitin ligase for Tau was recognized as the C-
terminus of heat-shock-protein 70 (Hsp70) interacting 
protein CHIP (Hatakeyama et al., 2004). Recent studies 
suggest that CHIP works in combination with heat shock 
proteins to regulate Tau degradation.  Levels of Hsp90 correlate inversely with the levels of soluble Tau 
and Tau oligomers, (Dickey et al., 2007; Sahara et al., 2007) however Hsp inhibitors, molecules that inhibit 
refolding but stimulate degradation, in this case Hsp90 inhibitors, seem to hold promise in reducing 
phosphorylation and misfolding of monomeric Tau through the UPS, it is unlikely that this strategy would 
Figure 10 - Structures of the compounds that inhibits Tau 
fibrillation  (Brunden et al., 2009) 
Figure 11 - Structures of the compounds that inhibits 
HSP90 (Brunden et al., 2009).  
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Figure 12 - The structures of the compounds that are 
involved in microtubule stabilization (Brunden et al., 2011).  
 
affect larger Tau oligomers and fibrils (Brunden et al., 2009)[Figure 13]. Immunosuppressant FK506 that 
reduces microgliosis and Tau aggregation in transgenic mice overexpressing P301S human 4R1N could be 
used as treatment by forming complexes with Hsps (Yoshiyama et al., 2007). Since this compound affects 
diverse signaling pathways in many cell types, it may act directly on neurons or influence the neuronal 
environment by modulating glial activation. Inhibition of Tau aggregation may also be mediated by direct 
binding of Tau to the FK506 binding protein (Morris et al., 2011) 
Larger aggregates of Tau are not likely to be accessible to the proteasome but degraded by the autophagy 
system. Studies demonstrated that addition of the autophagy inhibitor 3-methyladenine lead to enhanced 
Tau accumulation and Tau aggregation (Hamano et al., 2008). Consequently, this is a great evidence that 
aggregated Tau can be degraded by autophagy system and the upregulation of this system with drugs 
such as rapamycin, and nilvadipine, that blocks the calcium channel, might be a potential strategy for the 
treatments of Tauopathies (Tung et al., 2012). 
Increasing the activity of one or both of these catabolic systems may therefore lead to reduction of 
pathological Tau in AD and in the others Tauopathies (Brunden et al., 2009) 
 
Microtubule stabilization treatment 
As referenced before, Tau plays an important role in stabilizing microtubules within neuronal cell 
populations. In AD patient’s brains we can find a decrease in the number and length of microtubules and a 
reduction in the levels of MT-binding can be clearly linked to a disruption in Tau function (Himmelstein et 
al., 2012). In an attempt to compensate for the loss of 
Tau function, different research groups are testing 
different microtubule stabilizing compounds, like 
taxane, already used in cancer therapies. This has 
been deemed however unsuitable for Tauopathies, as 
it does not effectively penetrate the BBB and its side 
effects render it ineffective for long term use 
(Brunden et al., 2011).  
Nevertheless microtubule stabilization drugs currently in use for cancer treatments seem to be a good 
way to developed new treatments in Tau related disorders, as their metabolism and toxicity effects are 
already well established. Epothilone D (EpoD) it is one of most promising candidates, since it has been 
suggested that this compound can cross the BBB (Andrieux et al., 2006; Brunden et al., 2010).  In one of 
the studies with transgenic mice expressing the human Tau containing a PS19 mutation, EpoD treatment 
showed an improvement in microtubule density, in axonal integrity and what seems to be a reduction in 
cognitive decline (Brunden et al., 2010). Additional analysis of EpoD and other brain-penetrate MT-
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stabilizing agents are nevertheless necessary to provide more information about safety and efficacy 
before these compounds could be used for therapeutically approaches in Tau related disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
1.4. Tau clearance by intracellular degradation 
 
The trigger of Tau aggregation and Tau-induced neurodegeneration is still elusive. The impairment of 
protein-degradation systems might play a role in pathways that normally keep Tau levels at a low level 
which may prevent aggregation. The two major pathways that are associated with degradation of proteins 
are UPS and autophagy-lysosome-system. UPS system is the intracellular mechanism mostly responsible 
for degradation of short-lived proteins, whereas autophagy is associated with degradation of many long-
lived proteins and damage organelles.  The Hsp70/Hsp90 systems play also a critical role in the regulation 
of Tau degradation through proteasome system, and chaperones could also be involved in Tau 
degradation mediated by autophagy.  
In a initially stage of AD, UPS is the primary clearance system of pathological Tau, however the importance 
of autophagy-lysosome-system mediated Tau degradation is increased particularly in late stage of NFT 
formation.  
 
1.4.1. Contribution of UPS and autophagy in Tau degradation  
 
The UPS is a major cellular mechanism that regulates intracellular protein levels and eliminates damaged, 
misfolded and mutant proteins for protein quality control in cytoplasm and in nucleus (Lee, Lee, & 
Rubinsztein, 2013).  The proteasome is a protein complex consisting of at least 33 distinct subunits. 
Structurally and functionally, proteasomes comprise the 28-subunit core particle, also known as 20S 
Figure 13 - Summary of therapeutic strategies focused in Tau pathology (Adapted Brunden et al., 2009). 
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catalytic core, and the 19-subunit regulatory particle, also known as 19S particle (Kisselev, Callard, & 
Goldberg, 2006). The 20S catalytic core contains three types of subunits that execute trypsin-like, 
chymotrypsin-like and peptidylglutamyl-peptide hydrolyzing activities (Yipeng Wang & Mandelkow, 2012). 
The conical ubiquitin-proteasome pathway involves two steps: (i) UPS substrates are covalently 
conjugated with ubiquitin, a highly conserved 76-residue protein, that is involved in a cascade mechanism 
involving ubiquitin-activating enzyme E1, ubiquitin conjugated enzyme E2 and ubiquitin ligase E3; and (ii) 
degradation of the ubiquitinated protein by the 26S proteasome with the release of free and reusable 
ubiquitin (Shang & Taylor, 2011).  
The downregulation of enzymes E1 and E2 have been reported in AD (Shang & Taylor, 2011). The initial 
clue for the pathological link between Tau and UPS was derived from the frequent co-localization and 
accumulation of ubiquitin in PHFs and NFTs, since Tau ubiquitination occurs both in monoubiquitinated 
and polyubiquitinated forms (De Vrij, Fischer, Van Leeuwen, & Hol, 2004). Another study, reported a 
significantly decrease of trypsin-like activity in post-mortem AD brains (López Salon, Morelli, Castaño, Soto, 
& Pasquini, 2000),and this subunit seemed the most critical for the degradation of full-length Tau and its 
truncated forms. Another unclear area is how unfolded Tau proteins are recognized by proteasome and 
translocated in the active sites. One of the options is that Tau is slowly but constantly degraded through 
ubiquitin-independent process under normal conditions, as in stress conditions, Tau proteins are actively 
ubiquitinated by CHIP and removed by 26S proteasomes. Therefore, if we consider that most of the 
natively unfolded proteins are short-lived, and since Tau is relatively stable, ubiquitin-independent 
proteasomal degradation may be more responsible for Tau turnover than ubiquitin-dependent 
degradation. Some studies suggest that proteasomal dysfunction could be associated with beginning or 
facilitation of Tau aggregation process, however there is a reciprocal process between abnormal UPS 
activity and PHF formation, being the impairment of the proteasome function as a consequence of AD, 
instead of the cause of Tauopathies (Lee et al., 2013). 
Higher ordered oligomers and aggregates are more likely to be inaccessible to the narrow proteasome 
opening and these species are expected to have much higher dependency on autophagy for degradation. 
There are three type of autophagy: 1) macroautophagy that is the main pathway for eukaryotic cells to 
degrade long-lived proteins and organelles; 2). microautophagy where the lysosomal membrane directly 
engulfs part of the cytosol; and 3).chaperone-mediated autophagy, a type of selective autophagy 
targeting soluble cytosolic proteins containing a motif biochemically related to the pentapeptide KFERQ 
(Lys-Phe-Glu-Arg-Gln) (Wang & Mandelkow, 2012) . 
Autophagy involves the formation of a double-membrane vesicle termed the autophagossome and its 
sequestration of a portion of the cytoplasm. The completed autophagosome has a diameter of 300-900 
nm and matures by fusing with lysosomes to form autolysosomes, allowing hydrolysis of target substrates 
or organelles (Yorimitsu & Klionsky, 2005). In pathological AD brains an accumulation of autophagosomes 
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and autolysosomes was reported, suggesting that the basal autophagy process in neurons is abnormal in 
AD (Lee et al., 2013). 
Several studies, using neuronal ATG gene knockout mice, a gene essential for autophagy, revealed that 
autophagy is critical for normal neuronal health. They proved that with loss of either ATg5 or ATg7 
autophagy genes in CNS, an age-dependent accumulation of intraneuronal aggregates with 
polyubiquitination, inclusion formation and neurodegeneration occurred (Hara et al., 2006; Komatsu et al., 
2006). In a transgenic mice with overexpression of P301L Tau mutation, autophagy vacuoles were found 
to accumulate in neurons (Lin, Lewis, Yen, Hutton, & Dickson, 2003). An increase in the number of 
lysosomal complexes was also detected in neurons in transgenic mice expressing Tau with G272V, P301L 
and R406W mutations (Lim et al., 2001).   
Numerous experiments confirmed that the chemical inhibition of lysosomal degradation could delay Tau 
clearance, enhance Tau aggregation, and evoke cytotoxicity (Hamano et al., 2008),  
 
 
 
 
 
 
 
 
 
 
 
 
1.4.2. Chaperone complexes action on Tau protein to increase intracellular degradation 
 
In all cells, there are a large group of unrelated proteins which assist protein folding by reversible binding 
to unfolded and misfolded proteins and thus prevent their aggregation and facilitate formation of a 
correct conformation of a non-native protein. This group is called chaperones, and they can augment the 
functional activity of proteins, direct the cellular trafficking and also induce their degradation (Hartl, 1996). 
The chaperones only transiently interact with their substrate proteins and are not present in the final 
folded product (Turturici, Sconzo, & Geraci, 2011). One of the principal functions of molecular chaperones 
Figure 14 - Illustration of pathways involved in clearance of Tau protein. In early stage, the soluble Tau could be degraded 
by UPS ubiquitin dependent or independent mechanisms, however the Tau oligomers is inaccessible to UPS and are 
degraded by autophagy-lysosome system (Adapted from (Lee et al., 2013)).  
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Figure 15 - Mechanism suggested of chaperone/client pathway. A substrate may initially be recognized by the Hsp40/Hsp70 
complex with CHIP as the cochaperone/E3 ubiquitin (Ub) ligase. Transfer of the substrate to the Hsp90 complex is facilitated by 
Hop. There remain 2 fates for the substrate: dephosphorylation and refolding or ubiquitin-dependent proteasomal 
degradation. The mechanisms dictating which pathway is taken remain undefined. Hsp90 expression inhibits HSF1 activity by 
direct binding, which prevents HSF1 phosphorylation and trimerization. When Hsp90 is inhibited, Hsp90 levels are decreased, 
releasing HSF1, which in turn promotes de novo transcription of HSPs and stimulates the degradation pathway (Dickey et al., 
2007).  
is to retain protein quality during stressful insults (Salminen, Ojala, Kaarniranta, Hiltunen, & Soininen, 
2011).  
Heat shock proteins (Hsp) are protectors of cells against different kinds of stress. In mammalians, Hsp 
groups can be classified according to their proprieties into several families, Hsp70, Hsp90, Hsp60, Hsp40 
and small Hsps (Morimoto, Kline, Bimston, & Cotto, 1997). The transcriptional factor responsible for Hsp 
transcriptional activation is the heat shock transcription factor 1 (HSF1). According to the chaperone 
based model, HSF1 in unstressed cells is maintained is an inactive complex with Hsp90, Hsp40, and Hsp70. 
When increased Hsp levels are necessary in response to cellular stress, HSF1 is released from the complex 
and migrates to the nucleus, and leads to their upregulation (Pirkkala, Nykänen, & Sistonen, 2001)[Figure 
15].  
Hsps complexes can bind a large variety of client proteins, called clientele. The versatile chaperones 
complexes facilitates the maintenance of protein dynamics in cellular environment (Salminen, Ojala, 
Kaarniranta, Hiltunen, & Soininen, 2011). Hsps also exhibit a variety of cytoprotective functions, in 
addition to all other functions of this complexes by inhibiting the apoptosis cascade (Beere, 2004). In the 
nervous system, Hsp are induced in a variety of pathological states, including cerebral ischemia, 
neurodegenerative diseases, epilepsy and trauma. Their expression has been detected in multiples cells 
types, including neurons, glia and endothelial cells (Foster & Brown, 1997).  
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1.4.2.1. Chaperone – assisted Tau degradation  
 
Defective proteins will be initially labeled with ubiquitin tags in Hsp90 complexes. The co-chaperones 
Hsp70-interacting protein (Hip) and Hsp70/Hsp90-organizing protein (Hop) both interact with Hsp70 via 
their tetratricopeptide repeat (TPR) domains. In a screen for additional TPR-containing proteins, a protein 
named CHIP was identified. It was found that CHIP interacts with Hsp70 and inhibits its ATPase activity 
suggesting that CHIP might be involved in an Hsp70-mediated process distinct from refolding. CHIP can 
interact with either Hsp70 or Hsp90 through the same TPR, displacing them from Hop or other TPR-
containing proteins (Goryunov & Liem, 2007). This needs the recruitment of CHIP into the complex. CHIP is 
a co-chaperone with E3 ligase activity, highly expressed in the brain, cardiac and skeletal muscles.(Murata, 
Minami, Minami, Chiba, & Tanaka, 2001). These conjugating enzymes, linked to K48 ubiquitination, 
controls whether the protein will be directed to proteasomes. CHIP is associated with the MBD of Tau, and 
especially ubiquitinates the four-repeat Tau rather than the three-repeat counterpart. Later studies, 
revealed that the up-regulation of CHIP expression can attenuate Tau aggregation (Salminen et al., 2011). 
Previous studies in mice showed that a CHIP deficiency in this animal causes the accumulation of Tau 
protein, but does not causes Tau aggregation (Dickey, Yue, et al., 2006). This deficiency in mice also 
induces a decline in proteasome activity (Min et al., 2008).   
Several studies demonstrate that CHIP works in combination with Hsps to regulate Tau degradation, and 
levels of Hsp90 correlate inversely with the levels of soluble Tau and Tau oligomers (Morris et al., 2011) 
The chaperone mediated autophagy is a selective, chaperone-assisted uptake pathway for cytoplasmic 
proteins, guiding them to lysosomal degradation. Nevertheless, the uptake for this pathway needs a 
specific motif, KFERG-like sequence, in the protein and the uptake process requires a chaperone complex 
involving Hsp90, Hsp70 and Hsp40 (Bandyopadhyay, Kaushik, Varticovski, & Cuervo, 2008). Tau protein 
contains two pentapeptide motifs eligible for degradation by this pathway, the WT Tau has no affinity to 
chaperone-mediated autophagy uptake but instead, could be degraded via macroautophagy (Wang et al., 
2009). This indicate that aggregation-prone Tau protein can be degraded via macroautophagy which is a 
typical clearance pathway in multiple neuronal disorders involving proteins (Menzies, Ravikumar, & 
Rubinsztein, 2006).  
 
 
1.4.2.2.   Hsp70 in aggregation 
 
In contrast with other Hsps, Hsp70 proteins are found in almost all intracellular compartments. In humans, 
the Hsp70 multigene family includes the cytosolic and nuclear localization tag. Similar to the others 
chaperones, Hsp70 adopts three different conformations, one in the absence of a nucleotide, one with 
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Figure 16 - Representation of the current model for the 
conformational changes that accompany binding and 
hydrolysis of ATP by Hsp90 on the basis of structural and 
biochemical evidence. Inhibition of ATP binding by drugs, 
such as geldanamycin, blocks client protein activation 
(Pearl & Prodromou, 2006).  
ADP bound, and one with ATP bound (Turturici, Sconzo, & Geraci, 2011). This protein is involved in 
different chaperoning processes, such as refolding of misfolded or aggregated proteins, preventing 
protein aggregation, folding and assembly of nascent  polypeptides, and promoting the ubiquitination and 
degradation of misfolded proteins (Young, Barral, & Ulrich Hartl, 2003). The role of Hsp70 in folding of 
non-native proteins can be separated into three activities: prevention of aggregation; promotion of 
folding the native state; and solubilization and refolding of aggregated proteins (Mayer & Bukau, 2005). 
Molecular chaperones and components of the proteasome can also be found in aggregates formed in 
transgenic animal models and transfected cell cultures by various polypeptides, as intracellular Tau 
tangles. In various cellular models, increased levels of Hsp70 promote Tau solubility and Tau binding to 
microtubules, reduce insoluble Tau and cause reduced Tau phosphorylation (Dou et al., 2003; Jinwal et al., 
2010).  
Several studies, in recent years, have demonstrated that activation of the heat-shock response (HSR), and 
in particular elevation of Hsp70 levels, has a neuroprotective effect that is believed to be related mainly to 
its chaperone role. 
 
 
1.4.2.3. Heat shock protein 90 
 
The 90-KDa Hsps are ATP-dependent molecular 
chaperones that interact with many co-chaperones to 
fold proteins or targets misfolded proteins for 
degradation (Lu, Ansar, & Michaelis, 2009). This 
protein contain three domains; (i) N-terminal domain 
contains the binding site for adenine nucleotides and 
displays a low inherent ATPase activity; (ii) 
intermediate segment that interacts with client 
proteins; (iii) C-terminal domain mediates the 
dimerization of Hsp90 proteins and co-chaperone 
binding (Pearl & Prodromou, 2006).  
The ATPase domain is an important therapeutic target, 
since geldanamycin (GA), radicicol and their derivates, 
modulates at least two different conformational states, and can bind to and inhibit the action of Hsp90 
chaperone complexes (Pearl, Prodromou, & Workman, 2008) [Figure 16]. In general, Hsp90 complexes can 
assist in the folding process of proteins, stabilize them and even activate their clients. The most important 
regulators of this chaperone machinery are the co-chaperones and, the post-translational modifications of 
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the Hsp90 protein itself, for example acetylation, where this can inhibit the binding of clients to Hsp90, 
nitrosylation and phosphorylation (Wandinger, Richter, & Buchner, 2008).  
 
 
1.4.2.4.  Hsp90-CHIP complexes 
 
Different studies have demonstrated that CHIP protein, with the Hsp90 chaperone complex, has a key role 
in the removal of phosphorylated Tau protein. The same studies showed that CHIP does not recognize Tau 
proteins which are phosphorylated at normal Ser residues but binds only to mutant proteins and those 
which are phosphorylated at proline-directed Ser/Tyr sites. Therefore, the authors of this paper 
demonstrated that high-affinity Hsp90 binding complexes are present in the affected regions of AD brain 
but not in control samples (Dickey et al., 2007;Dickey, Dunmore, et al., 2006). Evidences suggested that 
Hsp90 forms a complex with mutated or distinctively phosphorylated Tau species and consequently 
recruit protein phosphatases, to facilitate dephosphorylating and refolding process (Goryunov & Liem, 
2007). There is a kind of phosphorylation code in Tau which determines whether the Hsp90 complexes 
dephosphorylate the Tau protein and enhance its binding to microtubules or recruit CHIP and mark the 
Tau with ubiquitin for degradation or in some contexts for aggregation. This evidence indicates that the 
effects of CHIP are neuroprotective rather than toxic (Dickey,Patterson, Dickson, Petrucelli, 2007). Minor 
perturbations in the chaperone system with aging may reduce the turnover of Tau, leading to aggregation 
and subsequent neurodegeneration (Dickey et al., 2007).  
 
 
1.4.2.5. Hsp90 complexes and Tau aggregation 
 
The functional role of Hsp90 chaperone in the aggregation of aberrant Tau protein is still largely unknown. 
However, this chaperone is associated with maintenance of the functional stability of neuronal proteins of 
aberrant capacity, thus allowing and sustaining the accumulation of toxic aggregates (Luo, Sun, Taldone, 
Rodina, & Chiosis, 2010). It is know that Hsp90 increase the stability of the oncoproteins and in that way 
can enhance cancerous growth (Luo, Rodina, & Chiosis, 2008). In neurodegenerative disorders associated 
with protein aggregation, the rationale has been that inhibition of Hsp90 activates HSF-1 to induce 
production of Hsp70 and Hsp40, as well as of other chaperones, which in turn, promote disaggregation 
and protein degradation (Muchowski & Wacker, 2005). Previous studies also demonstrated that Hsp90 
inhibition selectively reduced the level of Tau phosphorylated at proline-directed Ser/Tyr sites ( Dickey, 
Dunmore, et al., 2006).  
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When the cells are exposed to conditions of stress, the cells 
normally respond by activation of the HSR accompanied by 
increased synthesis of a number of Hsp which reduce 
cytotoxicity, such as caused by misfolded and denatured 
proteins (Muchowski & Wacker, 2005).  In mammals, 
protein damaging stress is regulated by activating of HSF-1, 
which binds to upstream regulatory sequences in the 
promoters of heat shock genes, and the function of HSF-1 is 
regulated by Hsp90 (Anckar & Sistonen, 2007).   
However, under non-stress conditions, Hsp90 binds to HSF-
1 and maintains the transcription factor in a monomeric 
state. In other words, stress, heat shock, or inhibition of 
Hsp90 release HSF-1 from the Hsp90 complex, which results in its trimerization, activation and 
translocation to the nucleus where it induce a heat shock response manifested in the production of Hsps 
such as the chaperones Hsp70 and its activator, Hsp40 (Brown, 2007). The function of Hsp90 can be 
inhibited by acetylation and subsequently blocks the binding of ATP to Hsp90 protein. This inhibits Hsp90 
and the clients are degraded in the same way as with drugs targeting directly the ATP binding motif (Bali 
et al., 2005). 
 
 
1.4.2.6. Hsp90 inhibitors 
 
As mentioned before Hsp90 assists in protein folding, it stabilizes various proteins including oncoproteins, 
it assists in protein degradation and it regulates HSF-1. Inhibition of ATP binding to Hsp90 with molecules 
such as GA enhances degradation of Hsp90 client proteins and results in the activation of HSF1 (Dickey et 
al., 2007).  
Previous studies identified that Hsp90 inhibitors promoted selective proteasome dependent degradation 
of aberrant p-Tau species in vitro, as well as induction of a significant reduction in the levels of both 
hyperphosphorylated and insoluble, aggregated mutant Tau in mouse brain (Dickey et al., 2007; Luo et al., 
2007). Treatments with Hsp90 inhibitors induce a time-dependent reduction in p35 levels and a clear 
decline in Tau phosphorylation, meaning that inhibition of Hsp90 can reduce Tau phosphorylation through 
the inhibition of p35-CDK5 (Salminen et al., 2011). Another Tau kinase, GSK-3ß, is also a client protein of 
the Hsp90 protein, and this chaperone regulates the autoactivation of GSK-3ß kinase. Diverse studies 
demonstrated that Hsp90 inhibitors can trigger the degradation of this kinase and thus inhibit it is activity 
(Banz et al., 2009).  
Figure 17 - Representation the role of Hsp90 
chaperone complexes in the regulation of, client 
protein of Hsp90, Tau protein modifications and 
trafficking (Salminen et al., 2011).  
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The first identified Hsp90 inhibitors used in vitro are GA, and radicicol, two natural products that were 
developed as antifungal agents, however this compounds are hepatotoxic for clinical use. Another class of 
Hsp90 inhibitors is Novobiocin analogues. These compounds do not compete for ATP binding, but have 
been found to be a novel promising class of C-terminal Hsp90 inhibitors ( Lu et al., 2009).  
Developed from GA, 17-allylaminogeldanamycin (17-AAG), is a less toxic inhibitor than GA, however, this 
compound has a very low brain exposure, making them not useful (Kamal, Boehm, & Burrows, 2004; Waza 
et al., 2006). This compound currently is in phase III clinical trial for cancer therapies (Salminen et al., 
2011). Hsp90 inhibitors, as GA, disturb the interaction between Hsp90 and HSF-1 and subsequently HSF-1 
triggers a heat shock response involving an increase in the levels of several chaperones, as Hsp70 and 
Hsp40. In cancer therapy, these have a protective role, exerting potent anti-apoptotic activity by inhibiting 
the assembly of the caspase-9-Apaf-1-cytochrome C apoptosome (Waza et al., 2006). However Dickey and 
colleagues demonstrated in neurodegenerative disorders, that Hsp90 inhibitors enhance Hsp90/CHIP – 
mediated p-Tau degradation helps to clarify the mechanisms of Tau metabolism and provides a possible 
therapeutic strategy for management of Tauopathies [Figure 18]. All these observations indicates that 
chaperone-mediated therapy could provide therapeutic benefits in AD, either by activating Hsp70, 
inhibiting other Hsps other than Hsp70, or stimulating HSF1 without Hsp90 inhibition. 
In summary, it has been shown that Hsp90 inhibitors seem to hold promise for reducing phosphorylation 
and misfolded monomeric Tau through the UPS (Brunden et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 - Components of the constitute chaperones system are required to facilitate degradation of aberrant Tau species by 
Hsp90 inhibitors, in turn refolding machinery prevents p-Tau degradation (Dickey et al., 2007). 
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1.5. Objectives  
 
The spreading and clearance of Tau are relevant processes in AD, so in an attempt to study these 
processes, validate possible targets and initiate drug discovery, it is extremely important to have relevant 
models as similar as possible to the pathological condition. In an attempt to identify a robust model to 
study pathological mechanisms that occur in AD, the main goal of this experimental project was to try to 
develop a seeding and aggregation model in vitro. 
Of all the existing models already described for Tau pathology, we directed our focus to a model 
developed by Guo and Lee who reproduced aggregation of Tau in a cellular context, similar to the 
pathological condition, making this a robust model to study aggregation process.  
In this project we optimized Tau aggregation seeding model in primary cortical neurons, with induction of 
aggregation by seeding with a synthesized and in vitro aggregated Tau fragment. Establishing a model 
related as much as possible to Tauopathy conditions could give us the possibility of studying alterations 
that occur in neuronal cells, such as post-translational modifications in presence of pathology, spreading 
of Tau protein in pathological case, pathways involved in endocitosis of pathological forms of Tau, as well 
as mechanisms involved in degradation of Tau. The strategy used in primary neuronal cultures was 
extrapolated from QBI cell seeding model, an already optimized model, with some adaptations, for 
example in neuronal cells we used an adeno-associated-viral vector serotype 6 (AAV6) to deliver 
hTauP301L gene in cultures instead of transient transfection of plasmid DNA. Our objective was then to 
optimize this model in primary cortical neurons, so that it can be a reproducible model to study Tau 
aggregation. 
In order to identify a compound that inhibits and/or delay Tau aggregation in QBI seeding model and in 
neuronal Tau aggregation model, we performed various tests in this model used an Hsp90 inhibitor, 17-
AAG, to evaluate its capacity of altering the process of Tau aggregation and contribute to Tau clearance.  
Identifying Tau-Tau interactions could be an essential way to understand AD mechanisms, as well other 
Tauopathies. Therefore, in an attempt to detect the interaction of Tau-Tau proteins in aggregation process 
in living cells, we used a bioluminescence resonance energy transfer (BRET) and Venus split 
complementation assay. This kind of strategies could be extremely useful to study different mechanisms 
that occur in cells in presence of Tau aggregated species. QBI seeding model was used for these assays, 
since this can reflect what physiologically happens in cells in Tau aggregation conditions. 
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Chapter 2                    Materials and Methods 
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2.1 Materials  
 
Table 3 - Materials used in this project. 
Company Product 
BD Falcon Tissue culture flasks (353028) 
Conical Tubes Screw Caps of 50mL(358206), 15mL(352097) 
Beckman Coulter Beckman centrifuge tubes (243775) 
Optima MAX-XP ultracentrifuge 
Bio-Rad Trans-Blot® Turbo™ Midi 0.2µM Nitrocellulose Transfer (170-4159) 
Trans-Blot® Turbo™ Transfer System #170-4150 
Santa Cruz Non-fat dry milk (NFDM) (sc-2325) 
Eppendorf 
Electroporation cuvettes, gap width 1mm, 100ml (4307 000.569) 
Eppendorf tubes of 0.5mL (022363719); 1.5mL (022363212) and 2 mL 
(022363344) 
Eurogentec SmartLadder (MW-1700-10) 
Falcon Multiwell plates of 96 (655946), 24 (354414) and 6 (354515) wells 
Genlantis BioPORTER Reagent QuikEase Single-Use Tubes (BP509696) 
HyClone Research Grade Fetal Bovine Serum(FBS) (SV30160.03) 
Life technologies 
B27 supplement (0080085SA) 
DMEM - Dulbecco’s modified Eagle’s medium (1956) 
Dulbecco's phosphate-buffered saline (D-PBS) (1X)     (-/- CaCl2; -/- 
MgCl2) (14190-094) 
E-Gel® Single Comb (G5018-08) 
HBSS - Hank's Balanced Salt Solution (14025076) 
Gibco® HEPES (15630-122) 
Horse Serum (26050088) 
iBlot® (IB3010-01) 
L-glutamine (25030) 
MagicMark™ XP Western Protein Standard (LC5602) 
MEM (31095) 
Neurobasal® Medium (21103-049) 
NuPAGE® LDS Sample Buffer (4X) (NP0007) 
NuPAGE® MOPS SDS Running Buffer (20X) (NP0001) 
NuPAGE® Novex® 4-12% Bis-Tris Gels, 1.0-mm thick, 12-well 
(NP322BOX) 
NuPAGE® Novex Bis-Tris Gels, 1.0-mm thick, 12-well  (WG14003BOX) 
NuPAGE® Reducing Agent (10X) (NP0009) 
One Shot® TOP10 Chemically Competent E. coli (C4040-10) 
One Shot® TOP10 Electrocomp™ E. coli (C4040-50) 
Opti-MEM® Reduced-Serum Medium (11058-021) 
Penicillin-Streptomycin antibiotic solution  (15140-122) 
S.O.C. Medium (15544-034) 
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UltraPure™ 5 M Sodium chloride (NaCl) (24740) 
Sodium Pyruvate 100 mM Solution (11360-039) 
UltraPure™ 1M Tris-HCI, pH 8.0 (15568-025) 
0.05% Trypsin-EDTA (1X) (25300-054) 
Merck Glucose (104074.1000) 
New England BioLabs 
BsgI Restriction Enzyme (R0559S) 
S-adenosylmethionine (B9003) 
Promega 
FuGENE® 6 Transfection Reagent (E2691) 
HaloTag® TMR Ligand (G825A) 
Nano-Glo® Luciferase (N1130) 
QIAGEN QIAGEN Plasmid Maxi Kit (12162) 
QIAprep Spin Miniprep Kit (27104) 
Roche 
cOmplete mini EDTA-free Mini Protease Inhibitor Cocktail Tablets 
(0469319001) 
PhosphoSTOP Phosphatase Inhibitor Cocktail Tablets (04906837001) 
Sigma-Aldrich 
Bicinchoninic Acid Kit for Protein Determination (BCA1-1KT) 
Goat serum (G9023) 
Heparin (H-5284) 
LB Broth-Liquid Medium (L2542) 
Sodium acetate –anhydrous (S2889) 
Lithium dodecyl sulfate (L2274) 
TWEEN® 20 (P1379) 
Triton™ X-100 (T8787) 
Thermo Scientific 
10X FastDigest Green Buffer (B72) 
FastDigest ® Eco91I (BstEII) (ER0391) 
FastDigest ® KpnI (ER0521) 
FastDigest ® NotI (ER0595) 
FastDigest ® XbaI (FD0684) 
SuperSignal* West Dura Chemiluminescent Substrate (34076) 
Restore ™ Plus Western Blot Stripping Buffer (46430) 
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2.2 Antibodies and Dyes 
 
Table 4 - Antibodies and dyes used in this project. 
Antibody/Dye Target Host Specie Company Application Dilution/ 
concentratio
n 
Anti-Actin Antibody, 
clone C4 
(MAB1501) 
Actin Mouse Milipore Western Blot 
1:10000 
Alexa Fluor® 555 Goat 
Anti-Mouse IgG (H+L) 
(A-21424) 
Mouse IgG 
Goat 
 
Life 
technologies 
 
Immunocytochemistr
y 1:10000 
Alexa Fluor® 488 Goat 
Anti-Rabbit IgG (H+L) 
(A-11008) 
Rabbit IgG Goat 
Life 
technologies 
Immunocytochemistr
y 1:10000 
Anti-HaloTag® 
Monoclonal Antibody 
(G921A) 
HaloTag fusion 
protein 
Rabbit Promega Western Blot 
1:1000 
Anti-NeuN, clone A60 
(MAB377) 
IgG Mouse Milipore 
Immunocytochemistr
y 1:100 
AT8 
Phosphorylate
d Tau on 
ser202/tre205 
Mouse 
Produced in 
house 
Western Blot and 
Immunocytochemistr
y 
1 µg/ml 
AT120 Human Tau Mouse 
Produced in 
house 
Western blot 
1 µg/ml 
Dako antibody (A0024) Tau Rabbit 
Dako 
cytomation 
Western Blot 
1:5000 
DAPI 
(62247) 
Double-
stranded DNA 
Not 
applicable 
Thermo 
Scientific 
Immunocytochemistr
y 1:5000 
ECL Mouse IgG, HRP-
linked whole Ab 
(NA931V) 
IgG Sheep 
GE 
Healthcare 
Life Sciences 
Western Blot 
1:10000 
ECL Rabbit IgG, HRP-
linked whole Ab 
(NA934V) 
IgG Donkey 
GE 
Healthcare 
Life Sciences 
Western Blot 
1:20000 
Hsp70/72 (AF1663) Hsp70 Rabbit R&D system Western Blot 
1:10000 
HT7 (MN1000 ) Human Tau Mouse Pierce 
Western Blot 
1:10000 
Immunocytochemistr
y 0.1 µg/ml 
Neuronal class III β-
Tubulin (MNS-435P) 
Tubulin beta-3 
chain 
Mouse Covance 
Immunocytochemistr
y 1:1000 
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2.3 Mammalian cell culture and Plasmid transfection 
 
Human kidney-derived QBI-293 (QBiogene) were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% (v/v) heat inactivated FBS, 1% Pyruvate (10 mM), 1% Penicillin-Streptomycin 
(PenStrep) and L-glutamine (20 mM). Cells were maintained at 37ºC, in humidified atmosphere containing 
5% CO2.  
One day prior to transfection, fully confluent cells were trypsinized and then seeded in 24 well plates at 
density of 5x104 cells per well. After 24 hours of growth, transfection was carried out using 3 μl FuGENE® 6 
reagent in 97 μl Opti-MEM medium with 5 minutes of incubation time at room temperature (RT). The 
nonliposomal-DNA complexes were obtained by mixing the transfection reagent with 1 μg of plasmidic 
DNA followed with incubation for 15 minutes at RT. This mix was added to the cells with 400 μl of 
antibiotic free medium. In case of co-transfections, the nonliposomal-DNA complexes were generated 
using 1 μg in total of desired plasmids. 
 
 
2.4 Primary neuronal culture and AAV transductions  
 
Primary neuronal cultures were prepared from E17-E18 Wistar WT rat embryos. Brains from embryos 
were dissected and kept in pre-warmed HBSS/Hepes solution (7 mM Hepes in HBSS and PenStrep) at 37ºC. 
Cortices were dissociated by trypsinization (4.5 ml HBSS/Hepes plus 500 μl of trypsin) for 10-15 minutes at 
37ºC. After removing trypsin, cortices were washed 3 times with pre-equilibrated MEM-Horse medium, 
supplemented with 10% (v/v) horse serum and 0.6% (v/v) glucose. Mechanical dissociation of biological 
material was made with pasteur pipettes of normal and small diameter in 3-5 ml of MEM-Horse medium. 
The cells were spun for 5 minutes at 1000 rpm, and ressuspended in 3 ml of MEM-Horse medium. The 
neurons were plated at a density of 6 x 105 cells/well in 6 well-plates coated with poly-D-Lysine or 1 x 104 
cells/well in 96 well-plates coated also with poly-D-lysine. After 4 hours the medium was changed to 
Neurobasal serum-free medium supplemented with 2% (v/v) B-27 and 10 mM L-glutamine. Neurons were 
maintained at 37ºC in 5% CO2 in humidified incubator. 
After 3 days of plating (day in vitro (DIV) 3) neurons were transduced with AAV6-hTauWT or AAV6- 
hTauP301L at a multiplicity of infection (MOI) of 100. Virus was diluted in Neurobasal medium with B-27 
straightaway before adding into the primary cultures.  
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2.5 In vitro fibrillization of recombinant Tau and fibril seeding 
 
A recombinant fragment of Myc tagged human Tau protein containing only the four MT-binding repeats 
designated K18, containing a P301L mutation (K18P301L) which is associated with Frontotemporal 
dementia and FTDP-17, was expressed in bacteria and purified using a fast protein liquid chromatography. 
In vitro fibrillization was stimulated by mixing 40 μM recombinant Tau protein (Myc-K18Tau-P301L) with 
40 μM of low molecular weight heparin and 2 mM DTT in 100 mM sodium acetate buffer (pH=7.0), 
incubated 3 days at 37ºC. Before seeding in cell lines and in neurons, the fibrilization mixture was 
centrifuged at 100000g for 30 min at 4ºC, and the resulting pellet was resuspended in an equal volume of 
100 mM sodium acetate buffer (pH=7.0) without heparin and DTT. Myc-K18Tau-P301L fibrils were stored 
as single-use aliquots at -80ºc.  
At the day of seeding K18P301L fibrils were diluted to 25 nM using 100 mM sodium acetate buffer (pH=7.0) 
and sonicated with 25 pulses of 2 seconds pulses, continuously on ice. Fibril seeding was performed in QBI 
cell line 24 hours after plasmid transfection, using BioPORTER reagent. 80 μl of K18P301L fibrils were 
added to one tube of BioPORTER reagent, gently vortexed for 5 seconds and allowed to stand at RT for 10 
minutes. During the formation of the fibrils-BioPORTER complex, cells were washed once with 200 µl 
OptiMEM. The fibril-BioPORTER complex was diluted with 1920 μl OptiMEM and 200 μl of the mixture 
were to each well. After 4 hours of incubation at 37ºC, QBI cells were trypsinated with 100 µl and 900 µl 
of DMEM was added to each well. The cells were re-plated in 96 well-plates at a cell density of 5x103 per 
well.  
In the experiments where BioPORTER reagent was used to seed primary neurons, the protocol used was 
the same as described with QBI cell line with Neurobasal medium instead of OptiMEM. In primary cortical 
neurons fibril seeding was done at DIV8 by adding the mixture of fibrils and Neurobasal medium 
supplemented with B27 directly to the neurons in the medium unless indicated otherwise.  
 
 
2.6 Sequential protein extraction 
 
QBI 293 cells were washed three times with D-PBS 48 hours after fibril seeding, while neurons were 
washed with D-PBS normally at DIV17 (unless indicated otherwise). In each well 160 µl triton lysis buffer 
were added (1% TritonX-100 in 50 mM Tris, 150 mM NaCl, pH 7.6) containing protease and phosphatase 
inhibitors and incubated 15 minutes at RT. After sonication in a water bath, cells were scraped and 60 μl 
of the total lysate was kept (total fraction) while the rest of the lysate material was centrifuged at 100 000 
g for 30 minutes at 4ºC. Supernatants were kept (soluble fraction) and the pellets were washed two times 
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with Triton lysis buffer, resuspended and metal tip sonicated in 100 µl LDS lysis buffer (1% LDS in 50 mM 
Tris, 150 mM LiCl, pH=7.6) until dissolved. One last centrifugation with the same speed was performed, 
and the supernatants were kept (insoluble fraction). 
 
 
2.7 Western Blot analysis 
 
After protein extraction of total, soluble and insoluble fractions, the soluble fraction was used to 
determinate protein concentration by a Bicinchoninic acid assay. 3 or 5 μg protein of each sample, relative 
to the protein concentration of the triton fractions, were loaded on NuPage Novex Bis-Tris 4-12% and run 
in MOPS SDS running buffer. The polyacrylamide gel was transferred to a 0.22 μm nitrocellulose 
membrane by Trans-Blot® Turbo™ Transfer System. Before probing membranes with primary antibodies, 
the membranes were blocked with 5% NFDM in TBS-T (1M Tris, 150nM NaCl and 0.05% (v/v) Tween-20, 
pH 8.5). After 1 hour of incubation at RT, membranes were incubated overnight with primary antibody in 
5% NFDM in TBS-T. Membranes were washed 3 times for 5 minutes with TBS-T followed by incubation 
with sheep anti-mouse IgG-horseradish peroxidase or donkey anti-rabbit IgG-horseradish peroxidase in 
TBS-T for 1 hour, at RT. Before signal detection, membranes were washed 4 times 5 minutes with TBS-T. 
Membranes were incubated with SuperSignal®West Dura Extended Duration Substrate and exposed for 
various times on the Lumi-Imager. To detect with different antibodies after exposing, the membrane was 
washed 3 times with TBS-T and incubated with 10 ml Restore™ Plus Western Blot Stripping Buffer, during 
15 minutes with shaking. After the membrane incubation with this buffer, the membranes were reprobed 
with different antibodies.  
 
 
2.8 Immunocytochemistry 
 
Immunocytochemistry was performed in primary cortical neurons plated in 96 well-plates 9 days after 
fibril seeding. Cells were fixated in 4% (v/v) of pre-warmed paraformaldehyde in D-PBS for 15 minutes and 
permeabilized with 0.1% (v/v) triton X-100 buffer in D-PBS for 10 minutes. Cells were rinsed 3 times for 5 
minutes with D-PBS, and incubated with blocking solution (5% (v/v) normal goat serum and 0.1% bovine 
serum albumin (BSA) (v/v) in D-PBS) for at least 30 minutes at RT. After blocking, cells were incubated 
overnight at 4ºC with specific primary antibody diluted in 0.1% (v/v) BSA in D-PBS. The next day neurons 
were washed 3 times for 5 minutes with 0.1% (v/v) BSA in D-PBS. Appropriated secondary antibodies 
diluted in 0.1% (v/v) BSA were added to neurons during 30 minutes. For nuclear staining DAPI diluted in D-
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PBS was added for 30 minutes and then washed with D-PBS. Fluorescent images were acquired using a 
Zeiss Axiovert 135 fluorescence microscope equipped with Zeiss Axiocam ICc1 camera and Zeiss Axiovison 
4.8 software using 20x objectives. The images were background corrected by ImageJ software. 
For cell viability quantification 4 images per well were captured using a multimode microscope reader 
MIAS-2 with 20x amplification. Cortical neurons fixed at different time points were quantified by manual 
counting using ImageJ software. At DIV8, 14, 16, 20, 22 in neurons transduced with AAV6 expressing 
P301L 30 repetitions were performed for each condition with and without seeding with pre-aggregated 
K18P301L. In neurons non transduced with AAV6 containing P301L 8 repetitions per condition were 
performed (with or without seeding with pre-aggregated K18P301L) in each day of fixating. 
The antibodies designated as A, B, C and D are confidential antibodies, therefore their characteristics 
cannot be mentioned.  
 
 
2.9 Cloning of Tau expression plasmids 
 
Nano-Luc, an ATP-independent luciferase, or HaloTag from Promega were cloned in-frame to the N-
terminal or C-terminal side of full-length Tau containing the two alternatively spliced N-terminal exons 
and four MT binding domains (2N4R Tau) with P301L mutation.  
Constructs were cloned into BstEII and XbaI sites of TauP301L-pcDNA4-TO vector. E.coli TOP10 cells were 
transformed with pcDNA4-TO plasmids encoding TauP301L-NanoLuc, NanoLuc-TauP301L, TauP301L-
HaloTag, and HaloTag-TauP301L through electroporation and plated overnight at 37ºC. 
TauP301L was also cloned in-frame with either the N-terminal (aa 1-155) or C-terminal parts of Venus 
fluorescence protein (aa 156-239) (Nagai et al., 2002). Also expression constructs for N-terminal and C-
terminal fusion proteins of both Venus fluorescent protein fragments with the mutant form of Tau, K18-
P301L, with only the MT-binding region, were generated by PCR.  
Similar constructs made with substitutions of two isoleucine residues at the positions of 277 and 308 to 
prolines were generated from K18-P301L. E.coli TOP10 cells were used to transform the plasmids 
encoding Venus constructs through electroporation and plated overnight at 37ºC. 
In all conditions previously described, Nano-Luc/HaloTag Tau constructs and Tau Venus constructs, a 
single colony was picked from a selected plate and inoculated in a culture of 5 ml Luria Broth medium with 
100 µg/ml concentration of ampicillin (selective condition). The bacteria were incubated for 12–16 h at 
37°C with vigorous shaking. To isolate and purify up to 20 µg of high-copy plasmid DNA from overnight 
cultures of E.Coli QIAprep Spin Miniprep Kit was used according to the manufactures protocol. 
Isolated plasmids were digested with BsgI and samples were analyzed on a 0.8 or 2% e-gel. The sequence 
of the clones that showed the expected pattern of DNA bands was confirmed by sequencing.  
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To have a larger amount of DNA to work with, 1 ml of bacterial cell culture was inoculated in 100 ml of 
Luria Broth medium with 100 µg/ml ampicillin. The plasmid was purified from these bacteria using the 
QIAGEN Maxi Kit. To determine the yield, DNA concentration and purity was determined with NanoDrop® 
1000, by the absorbance of coefficient between 260 nm and 280 nm. 
 
 
2.10 BRET assay 
 
QBI 293 cells were co-transfected with plasmids of interest as described earlier, with HaloTag fusion 
proteins in molar excess to Nano-Luc fusion proteins. The HaloTag™ TMR ligand was used as BRET 
acceptor and NanoLuc™ Luciferase was used as BRET donor. 24 hours after fibril seeding, QBI cells were 
treated with 100 nM of HaloTag™ TMR ligand and incubated overnight at 37ºC in 5% CO2. On the day after, 
NanoLuc™ Luciferase substrate was diluted 1:250 in Opti-MEM, added to the cells, and HaloTag 
fluorescence and Nano-Luc luminescence signal was measured and BRET efficiency was calculated based 
on that. 
The Nano-Luc luminescence signal was detected using a 450 nm emission filter and HaloTag fluorescence 
was measured with second 585 nm emission filter using a Perkin Elmer EnVision 2102 Multilabel Reader. 
BRET ratio is calculated using the quotient between the average of the readout at 585 nm and the readout 
at 450 nm in wells treated and not loaded with HaloTag™ TMR ligand. Statistical analysis was made by 
GraphPad Prism®5 software. 
Equations shown below correspond to the way we calculated BRET assay ratio. The reading at 585 nm 
corresponds to HaloTag measurement wavelength, whereas 450 nm correspond to Nano-Luc 
measurement wavelength. Conditions 1 and 2 correspond to the different conditions of each experiment.  
 
Equation 1 
 
 
 
 
Equation 2 
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Equation 3 
 
 
 
 
 
2.11 Venus split complementation assay 
 
QBI 293 WT cells were co-transfected with plasmids of interest as described early, with different 
combinations of Tau-Venus fusion expression constructs. Cells were seeded with pre-aggregated fibrils (as 
previously described) 24 hours after the co-transfection with indicated constructs.  
Venus fluorescence signal was detected using an excitation filter of 515 nm and an emission filter of 528 
nm, by a fluorescence microscope. Fluorescent images were acquired using a Zeiss Axiovert 135 
fluorescence microscope equipped with Zeiss Axiocam ICc1 camera and Zeiss Axiovison 4.8 software using 
20 x objectives.  
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3.1 Optimization of the cellular Tau aggregation model in cortical primary neurons 
 
3.1.1. hTauP301L aggregation model  
 
The first goal of this project was to optimize the aggregation model in cortical primary neurons. Previously 
a Tau aggregation model was developed in a QBI 293 cell line, but since the objective of the model was to 
mimic as closely as possible the Tau pathology that occurs in the brain of AD patients, an effort was made 
to optimize the Tau aggregation model in rat cortical primary neurons. 
The same strategy used in the QBI cell model was applied to cortical primary cultures. Neurons were 
transduced with AAV6 containing WT Tau or P301L-Tau that will be express under the neuron specific 
SYN1 promoter 3 days after plating of the neurons (Figure 19). Tau aggregation, like in the QBI 
aggregation model, is a process that is not spontaneous just with the presence of protein hTauP301L. To 
overcome the rate limiting step of the initial aggregation it is necessary to treat the neurons with in vitro 
pre-aggregated K18P301L that can function as an aggregation seed. For this studied we used, K18P301L a 
synthetic fragment of Tau containing only the four MT-binding repeats with a mutation where a proline is 
changed to a leucine at position 301 (position in the longest isoform of Tau). Previous experiments in our 
group showed that the best time point to add K18P301L fibrils was 8 days after neuronal plating. Tau 
aggregation in this model was studied either by biochemical analysis or by immunocytochemistry analysis 
generally 17 days after neuronal plating (Figure 19). 
 
 
The capacity of in vitro pre-aggregated K18P301L to induce intracellular aggregation of hTauP301L was 
visualized by immunocytochemistry. Neurons transduced with AAV6 containing hTauP301L were seeded 
with or without pre-aggregated fibrils (Figure 20). Human total Tau present in neurons was labeled with 
the HT7 monoclonal antibody which recognizes epitopes of human Tau between residues 159-163, 
whereas the induced aggregated Tau was detected with the antibodies A, B, C, D, and AT8. No signal was 
Figure 19 – Schematic representation of strategy used in Tau aggregation model in cortical primary neurons. DIV represents 
the days that neurons are in culture after plating. 
 DIV 0: Plating of 
cortical neurons
DIV 3: Transduction with 
AAV6-hTauP301L / AAV6-hTauWT
DIV 8: Seeding with 
K18P301L fibrils
DIV 17: Triton/LDS neuron extraction 
or Immunocytochemistry analysis
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detected with HT7 in cells not transduced with hTauP301L and no seeded with pre-aggregated K18P301L, 
since HT7 is a human specific antibody that does not detect rat Tau (Figure 20A). A similar result was 
obtained with specific antibodies to pathological forms of Tau (Figure 20D, G, J, M, P). When neurons were 
transduced with hTauP301L we were able to see human Tau in neuronal cultures, by HT7 staining (Figure 
20B). To discriminate between neurons and astrocytes all samples were co-stained with ß3-tubulin and a 
nuclear strain. The HT7 staining was only observed in cells positive for ß3-tubulin expression. In conclusion, 
we found a clear expression of Tau specifically in the neurons when they were transduced with AAV6-
hTauP301L.  
Augustinack et al. showed that the immunoreactivity of AT8 antibody is associated with different stages of 
NFT formation in AD human brains (Augustinack et al., 2002). In the conditions where neurons were not 
seeded with pre-aggregated K18P301L no signal with antibodies against pathological forms of Tau was 
observed suggesting that Tau does not aggregate under this condition (Figure 20E, H, K, N). However, 
under these conditions we did observed a weak immunoreactivity for AT8, a monoclonal antibody specific 
to double phosphorylated Tau epitopes at Ser202 and Tyr205 (Figure 20Q). This suggests that hTauP301L 
is at least partially phosphorylated at the AT8 epitope in neurons upon overexpression. On the other hand, 
in neurons transduced with hTauP301L and seeded with 25nM of in vitro pre-aggregated K18P301L a 
strong increase in staining was observed with the aggregation specific antibodies A, B, C, and D and with 
AT8 suggesting the induction of Tau aggregation in these cells (Figures 20F, I, L, O, R). The staining of 
aggregated Tau was observed as green dots along dendrites. The induction of a dotted staining pattern of 
Tau after seeded with pre-aggregated K18P301L was also observed with AT8 suggesting that this 
treatment produced AT8 positive dots, correspondent with pathological cases of Tau pathology. In Figure 
20I the presence of a structure similar to NFT is evident, which is found in pathological human brain, 
meaning that the Tau aggregation model that we are using could be a promising model to study the 
aggregation occurring in AD patients brains. With all these observations we can conclude that for inducing 
a pathological conformation in Tau, the presence of pre-aggregated fibrils is necessary to induce 
aggregation of unfolded hP301L-Tau. 
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Figure 20 - Immunocytochemistry analysis of cortical primary neurons transduced with or without AAV6 containing P301L-Tau 
and with or without seeded with pre-aggregated K18P301L. Immunocytochemistry analysis of paraformaldehyde fixed cells. Red 
staining corresponds to ß3-tubulin, blue to DAPI staining and green to specific antibody stain (antibody used stated in the Figure). 
HT7 staining shows the presence of total human tau; Antibodies A, B, C, D and AT8 show specific staining for pathological Tau in 
cortical neurons induced by K18P310L fibrils. Images were acquired by a fluorescence microscopy with magnification of 20x. In 
contrast images P, Q and R were not stained with DAPI, and these images were acquired by confocal microscopy with magnification 
of 20x. Scale bar: 219 µm. (Note: Antibodies A, B, C and D were designated by this way due the confidentiality reasons.)  
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3.1.2. Spontaneous uptake of in vitro pre-aggregated K18P301L in cortical primary cultures 
 
As a first approach to optimize the Tau aggregation model in cortical primary neurons, we tested the 
effect of the use of BioPORTER delivery reagent with K18P301L seeds. BioPORTER reagent interacts non-
covalently with the molecule of interest and delivers it into the cells using a lipid-based carrier system.  
In the previous model developed in QBI 293 cell line, BioPORTER reagent is crucial to delivery in vitro of 
pre-aggregated K18P301L to the cells. Based on this fact the introduction in neurons of pre-aggregated 
fibrils was performed using this reagent as well. This reagent however was highly toxic to neurons, since 
neurons showed a visible damage in presence of the BioPORTER (data not shown). Taking this fact into 
account we tested the requirement of this reagent for the delivery of K18P301L fibrils. Therefore, we 
added 10 µM of pre-aggregated K18P301L to one tube with or without of BioPORTER delivery reagent and 
diluted this in 920 µl of neurobasal medium without B27 supplement. Different amounts of these fibrils 
complexed with or with BioPORTER were added to neurons plated in 6-well-plate that were previously 
transduced with AAV6 containing P301L-Tau (Figure 21). 8 days after K18P301L seeding, cells were lyzed 
and proteins were separated in soluble and insoluble fractions by ultracentrifugation. Samples were 
analyzed by western blotting using the anti-Tau antibody HT7, which detects human Tau in the residues 
between 159-163 (absent in the in vitro synthetic K18P301L). hTauP301L was only detected in the 
insoluble fraction after seeding with pre-aggregated K18P301L fibrils. In the total fraction a shift in the 
apparent molecular weight of the Tau band was observed after seeding with the fibrils. This may be due to 
an increase in phosphorylation of aggregated Tau causing the protein to migrate significantly slower in the 
SDS-PAGE gel compared with non-phosphorylated Tau. After separating soluble and insoluble proteins we 
found that the slower migrating form of Tau was insoluble and the faster migration was soluble. Induction 
of Tau aggregation after fibril transduction was also observed in the conditions where BioPORTER delivery 
reagent was not used. Curiously, lower concentrations of in vitro pre-aggregated K18P301L in absence of 
BioPORTER, seemed to show the higher levels of hTauP301L aggregation than higher concentrations of 
pre-aggregated K18P301L. However, we cannot extrapolate this conclusion, since there is a lot of variation 
in this western blot. Tau aggregation relative quantification was performed to have a more quantitative 
view on the western blot results (Figure 21B) confirming what is seen in the western blot. 
These results suggest that fibril uptake in primary neurons is different than in QBI cells, there seems to be 
a spontaneous uptake of fibrilar Tau, leading to an induction of pathological aggregates in neuronal 
cultures. These data suggests that we do not need to use BioPORTER delivery reagent to induce 
hTauP301L aggregation in cortical primary neurons. Therefore, in future experiments BioPORTER will no 
longer be used, because of its toxicity to neurons, and without its use, it is possibly to study the uptake of 
seeds as a step in the Tau aggregation cascade. 
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Next we tested the effect of B27 supplementation in the neuronal culture medium on hTauP301L 
aggregation, without BioPORTER presence. B27 is a protein-rich supplement for long-term cultures. 
Previous experiments had shown that B27 supplementation greatly reduces uptake of Fibril/BioPORTER 
complexes. 
Therefore the medium on the cortical primary neurons was replaced with new medium with or without 
B27 supplement before seeding with 1 µM of synthetic pre-aggregated K18P301L fibrils. The medium was 
changed again to neurobasal medium supplemented with B27 4 hours after the K18P301L fibril seeding.  
Figure 21 – Analysis of sequentially extraction of proteins from cortical primary neurons seeded with different 
concentrations of pre-aggregated K18P301L with or without BioPORTER delivery reagent. (A) Western blot analysis of cortical 
primary neurons with transduction with P301L-Tau and seeded at DIV8 with 1µM, 2µM, 4µM, 10µM or 40µM of K18P301L 
fibrils with or without BioPORTER reagent. Equal portions of extracted protein were loaded on SDS-polyacrylamide gels. 
Monoclonal antibody HT7 against human total Tau was used and actin antibody was used as control of protein amounts. (B) 
Quantification of Tau in insoluble fraction band (normalized to actin), in 0.22 μm nitrocellulose membrane. N=2, average ± SD. 
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The effect of B27 supplement on Tau aggregation induction was analyzed by western blot (Figure 22). 
hTauP301L was observed in the insoluble fraction only in samples from neurons transduced with AAV6-
hTauP301L and seeded with K18P301L fibrils. This was independent of the presence of the B27 
supplement. In conclusion there was no need to remove B27 supplement from the medium during fibril 
seeding in neurons. This way, the management of the neurons is easier and they are less exposed to 
possible ambient damages, since manipulation is reduced by one step. 
 
 
 
3.1.3. Cellular viability of hTauP301L neuronal aggregation model  
 
In conformity with our main objective, the optimization of hTauP301L aggregation model in cortical 
primary neurons, we tested the effect of hTauP301L expression and aggregation on cellular viability in this 
model at different time points, during 22 days in culture. Therefore, cortical neurons with or without 
transduction with AAV6 containing P301L-Tau and with or without seeding with pre-aggregated K18P301L 
were fixed at different time points. Samples were stained with a NeuN antibody which recognizes DNA-
binding neuron-specific protein NeuN and DAPI, a nuclear acid stain that binds preferentially to double-
stranded DNA (Figure 23A). 
In Figure 23A the morphology of neurons after different days of culture is shown, where DIV0 corresponds 
to the day that the neurons were plated. The DIV0 neurons were fixed with paraformaldehyde 19 hours 
after plating (Figure 23A, panel A). 
We noticed that with an increase in culture days the density of NeuN positive cells decreased as well the 
total number of the cells. This suggests a decrease over time in the neuron density as well the number of 
non-neuronal cells, although with a slower rate since we observed a higher relative amount of non-
neuronal cell compared with neurons overtime. 
Figure 22 - Western Blot analysis of the effect of 
B27 supplement during fibril seeding on efficiency 
of aggregation induction in neurons. Cortical 
primary neurons were transduced with or without 
P301L-Tau at DIV3 and also seeded with 1 µM pre-
aggregated K18P301L at DIV8 in the presence or 
absence of B27. In neuronal samples where 
K18P301L fibrils were added to neurons in the 
absence of B27, the medium was changed 4 hours 
later to Neurobasal medium supplemented with 
B27. Equal portions of extracted protein were 
loaded on SDS-polyacrylamide gels. The human 
total Tau was detected used HT7 monoclonal 
antibody, equal protein loading was confirmed by 
actin antibody. 
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Viability of the neurons was quantified by manual counting of the NeuN positive cells after different days 
of fixation (Figure 23B). We observed (Figure 23) an increase in the number of NeuN positive cells of about 
30% between DIV0 and DIV3, likely due to a fixation artifact, since it will be expected that on DIV0 all 
neurons present in culture are already expressed NeuN protein. Between DIV3 and DIV16 around 65% of 
the neurons in culture died. From DIV16 until DIV22 there was not an obvious further decrease in cell 
viability. Transduction with AAV6-hTauP301L or seeded with pre-aggregated K18P301L did not affect 
neuronal survival (Figure 23A and 23B). Also the combined transduction with AAV6-hTauP301L and 
seeded with pre-aggregated K18P301L showed no effect on neuronal survival rate. Even at higher 
concentrations of pre-aggregated K18P301L (100 nM and 50 nM) no noticeable difference in mortality of 
neurons was observed (data not shown).   
These data suggests that transduction with AAV6-hTauP301L by itself, seeded with pre-aggregated 
K18P301L, and induction of intracellular Tau aggregation does not have a neurotoxic effect in hTauP301L 
neuronal aggregation model, and it was not observed a dotted staining pattern indicative of damage to 
dendritic structures. 
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3.1.4. Effect of K18P301L on hTauP301L and hTauWT aggregation kinetics in cortical primary 
neurons 
 
Next we wanted to test the effect of the P301L mutation on Tau aggregation kinetics in primary neurons. 
Therefore, we compared the efficiency of aggregation of hTauP301L and hTauWT. At DIV3 cortical 
neurons were transduced with AAV6-contaning either P301L-Tau or WT Tau that will be express under the 
neuron and were seeded with different concentrations of in vitro pre-aggregated K18P301L at DIV8. 
Evaluation of efficiency of the procedure was done by western blot analysis, through the observation of 
the presence of Tau aggregation in both transduction conditions (observed in the insoluble fraction). We 
used two different antibodies to detect total Tau, AT120 which detects total Tau in an epitope between 
residues 215 and 227, and HT7 antibody, and Tau phosphorylation was studied with AT8.  
Upon AAV transduction hTauP301L and hTauWT protein was detected in total lysate with both total Tau 
antibodies (Figure 24). Upon seeding with fibrils, different forms of hTauP301L were detected with HT7 
one of which was AT8 positive and insoluble. In contrast, fibril transduction did not induce aggregation on 
hTauWT, and the presence of phosphorylation in AT8 epitope was not detected and caused no change in 
gel mobility. In addition, no insoluble hTauWT could be detected under these conditions. We did not 
observe (Figure 24) hTauP301L protein in insoluble fraction in neurons seeded with 10nM of fibrils with 
AT120. We can conclude that in vitro pre-aggregated K18P301L can induce Tau aggregation of hTauP301L 
but not of hTauWT in this cortical neuronal model. 
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Figure 23 – Effect of AAV6 P301L-Tau transduction and pre-aggregated K18P301L seeding on cell viability of cortical neurons. 
Cortical primary neurons with or without transduction with AAV6 on DIV3 were seeded with or without 25 nM K18P301L. Cells 
were fixed at different time points DIV0, 3, 8, 14, 16, 20, 22. (A) Immunocytochemistry analysis of paraformaldehyde fixed cells. 
Blue staining corresponds to DAPI staining all cells, and green to the neuron specific NeuN antibody staining. Images were 
acquired by a multimode microscopy reader MIAS-2 with magnification of 20x. Scale bar: 422 µM. (B) Quantification of 
neuronal cell viability (%) was assessed by manual counting using Image J software. 8 replicates were counted for cells not 
seeded with K18P301L fibrils, and 30 for cells seeded with K18P301L fibrils. Depicted is the average ±SEM 
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3.1.5. Effect of extracellular fibril concentration in cortical primary neurons 
 
We aim to develop the Tau aggregation model to identify compounds, genes, and pathways that may 
modulate the Tau aggregate uptake, build-up and degradation. To optimize the sensitivity of the model 
we investigated the minimal concentration of fibrils needed to induce intracellular Tau aggregation. 
Previous results showed that without using any delivery regent it was possible to induce hTauP301L 
aggregation in neurons already with 1 µM K18P301L fibrils (see Figure 21). Therefore, we examined the 
level of hTauP301L aggregation in neurons seeded with 1-100 nM pre-aggregated K18P301L fibrils (Figure 
25). We observed a strong hTauP301L aggregation in neurons seeded with 100 nM, 50 nM, and 25 nM of 
pre-aggregated K18P301L, since we saw a strong signal with HT7 antibody in the insoluble fraction (Figure 
25A). However, compared to the data show above, we could not detect similar results with 10 nM and 3 
nM of K18P301L fibrils, with these amounts only a weak Tau signal was observed in the insoluble fraction 
(Figure 25A). Tau aggregation relative quantification was performed to have a more quantitative view on 
the western blot results, and it clear that there is more hTauP301L aggregation in neurons treated with 50 
nM of pre-aggregated fibrils compared with neurons treated with a higher amount of fibrils (100 nM). 
There is however a clear variation between repetitions within the same condition (Figure 25). However, 
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Figure 24 - Analysis of sequential extraction of proteins from cortical primary neurons transduced with AAV6 containing 
wild-type Tau or P301L Tau. WB analysis of total and insoluble fractions of cortical primary neurons transduced with P301L Tau 
or with WT Tau and seeded with different concentrations of pre-aggregated K18P301L at DIV8. Equal portions of extracted 
protein were loaded on SDS-polyacrylamide gels. Monoclonal antibodies HT7 and AT120 against human total Tau were used, as 
well as the phosphorylation-dependent anti-Tau antibody AT8. Actin antibody was used as control for protein amounts. 
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we could not detect hTauP301L in the insoluble fraction from cortical neurons seeded with 1 nM of pre-
aggregated K18P301L fibrils (Figure 25B). Taking this into account, we can presume that this concentration 
of K18P301L is not enough to induce Tau aggregation. 
Considering the data shown, we chose to use in further experiments 25 nM of fibrils, not being however 
the concentration that showed stronger aggregation levels but this concentration showed an adequate 
induction of hTauP301L aggregation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.6. Kinetics of Tau aggregation in primary neuronal model 
 
With the objective to continue the optimization of the Tau aggregation model in cortical primary neurons, 
the variation of kinectics of Tau amyloidogenic aggregation process with different exposure time to in 
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Figure 25 –Analysis of the effect of different K18P301L fibril 
concentrations on efficiency of Tau aggregation in cortical 
primary neurons. (A) WB analysis of cortical primary 
neurons transduced or not with P301L-Tau and seeded or 
not with 100 nM, 50 nM, 25 nM, 10 nM, 3 nM, or 1 nM 
K18P301L at DIV8. Equal portions of extracted protein were 
loaded on SDS-polyacrylamide gels. Monoclonal antibody 
HT7 against human total Tau was used and actin antibody 
was used as control of protein amounts. (B) Quantification 
of insoluble fraction band (normalized with actin), in 0.22 
μm nitrocellulose membrane. N=3 for all fibril concentration 
excepted for 100 Nm of fibrils (N=2), average ± SD . 
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vitro pre-aggregated K18P301L was analyzed. Primary cultures were seeded with the same quantity of 
fibrils (25nM), and then we did protein extraction at different time points, 14, 17, 20 and 22 days after 
neuronal plating (Figure 26). For aggregated Tau detection we used HT7 antibody (human total Tau) and 
AT8 antibody (human phosphorylated Tau) in western blot analysis. 
Aggregated Tau species with a molecular weight of ~ 65 KDa were observed in the insoluble fraction from 
cortical neurons after 14 days in culture. An increased in amount of aggregated Tau was seen in neurons 
after 3 more days of culture (17 days) (Figure 26). We observed (Figure 26B) a small increase in Tau 
aggregation detected with HT7 antibody, over the next 3 day in culture (20 days), which reaches a plateau 
between DIV20 and 22. These results could be confirmed, with quantification of Tau aggregation on 2 
different experiments however these kinetics could not confirmed with the AT8 antibody. The high degree 
of variation in this assay requires multiple replications to reach a conclusion with statistical significance. 
These results suggest that hTauP301L aggregation increases with time however we could not conclude 
that an increase in Tau aggregation is a consequence of a propagation of toxic Tau fragments, which could 
be occurring in neurons. Considering the data shown, we should choose the DIV14 to perform the 
sequentially protein extraction instead of DIV17 as we had been using. The difference in Tau aggregation 
between DIV14 and 17 was small but the increase in neuronal death was significant (as shown in Figure 
23).  
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3.2. Testing Hsp90 inhibitors to decrease Tau aggregation  
 
3.2.1. Effects of 17-AAG on Tau aggregation in the neuronal aggregation model  
 
As described in the introduction (see section 1.4.2) the Hsp90 complex is involved in the clearance of 
misfolded Tau, leading to a decrease in phosphorylated Tau levels. Hsp90 inhibitors have been extensively 
studied as possible cancer therapies, and are also being explored as treatment for neurodegenerative 
diseases. Hsp90 inhibitors seem to hold promise for reducing phosphorylated and misfolded monomeric 
Tau through the UPS (Brunden, Trojanowski, & Lee, 2009;Wang & Liu, 2008).  
With this information, our group has studied the effects of Hsp90 inhibitors on the development and 
clearance of Tau aggregates. Therefore we used 17-AAG, an Hsp90 inhibitor derived from GA that was 
reported to be less toxicity than GA in in vivo studies, using mice and dogs (Supko, Hickman, Grever, & 
Malspeis, 1995).  
The potential of 17-AAG to clear Tau was evaluated in the Tau aggregation model in cortical primary 
neurons. Previous work in our group with 17-DMAG, another Hsp90 inhibitor, showed that there was an 
active inhibition of the Hsp90 activity and an evident decrease in hTauP301L aggregation in neurons 
treated with this compound. Based in this data we also tested the role of 17-AAG compound in neurons. 
17-AAG was the chosen compound to test instead of 17-DMAG since the former in previous results 
Figure 26 - Sequential analysis of protein extracted from cortical primary neurons at different times after fibril seeding. (A) 
WB analysis of cortical primary neurons transduced with AAV6 containing P301L-Tau and seeded with or without pre-
aggregated K18P301L. Cortical neurons were extracted at different time points after K18P301L seeding. Equal portions of 
extracted protein were loaded on SDS-polyacrylamide gels. Monoclonal antibody HT7 against human total Tau was used, as 
well AT8 - phosphorylation-dependent anti-Tau antibody, and actin antibody was used as control for protein amounts (B) 
Quantification of insoluble fraction band of the 2 WB gels (normalized to actin), in 0.22 µm nitrocellulose membrane. N=4, 
average± SD. 
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presented high toxicity levels for neurons in our Tau aggregation neuronal model, and thus possibly 
compromising the results obtained. 
Cortical primary neurons were treated with different concentrations of 17-AAG, and the aggregation of 
hTauP301L was induced by 1 µM of pre-aggregated K18P301L. The toxicity of this compound for the 
neurons was shown in Figure 27A, where we can see a morphological alteration in the neurons treated 
with this compound. With exposure over time to the compound vacuolization started to appear and later, 
neurites disappeared (Figure 27AII).  
To detect the presence of human Tau we used HT7 antibody, and an Hsp70 antibody was used to verify 
the activity of 17-AAG since Hsp90 inhibition releases a transcription factor that activates the transcription 
of various Hsps including Hsp70 in western blot analysis. We can see (Figure 27B) that the HT7 signal 
decreased with an increased 17-AAG concentration. That means that we can detect a decrease in 
hTauP301L aggregation signal with 1 µM, 3 µM and in 10 µM of 17-AAG. With lower concentrations of this 
compound (0.1 µM and 0.3 µM) we could not detect an effect of this compound on Tau aggregation, since 
in this case the levels of protein present in insoluble fraction in conditions treated and not treated with 
17-AAG seemed be the same (Figure 27B). However in all of conditions some variation occurred between 
the triplicates, although the decrease in hTauP301L aggregated levels was consistent. With Hsp70 
antibody we identified that levels of hTauP301L aggregation are inversely correlated with Hsp70 
expression (Figure 27B), as we expected. However, the effect of Hsp90 inhibitors on soluble and insoluble 
Tau levels are directly correlated with toxicity levels of these compounds which mean that we could not 
confirm Hsp90 inhibition to be a viable drug target for AD. 
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3.2.2. Effect of 17-AAG in QBI seeding model  
 
To test the effects of Hsp90 inhibitors on the development and clearance of Tau aggregates we evaluated 
the role of 17-AAG in the QBI seeding model. QBI cells were treated with different concentrations of 17-
AAG 6 hours after seeding with 10 µM pre-aggregated K18P301L with BioPORTER reagent and the effects 
of the treatment on Tau aggregation was detected by western blot analysis (Figure 28). To detect the 
presence of human Tau we used HT7 antibody, and an Hsp70 antibody was used to verify the activity of 
17-AAG in a western blot analysis. We could detect a clear hTauP301L aggregation in cells not treated with 
Hsp90 inhibitor, as well in cells treated with lower concentrations of the compound (0.1 µM and 0.3 µM) 
(Figure 28). However, when cells were treated with higher concentrations (3 µM and 10 µM) of 17-AAG, 
Tau aggregated signal was highly reduced, since we could not detected presence of protein in insoluble 
fraction (Figure 28A). Tau aggregation relative quantification was performed to have a more quantitative 
view on the western blot results (Figure 28B) and it we clearly observed a decrease in Tau aggregated 
protein with an increase in 17-AAG concentration.  
Figure 27 – Analysis of cortical primary neurons treated 48 hours before extraction with different concentrations of 17-AAG. 
(A) Microscopy images of cortical primary neurons at DIV 17 (I) untreated neurons and (II) 48 hours after neurons treated with 
1µM of 17-AAG. (B) WB analysis of cortical primary neurons seeded or not with 1 µM of pre-aggregated K18P301L at DIV8, and 
treated or not treated with 0.1 µM, 0.3 µM, 1 µM, 3 µM and 10 µM of 17-AAG compound. The human total Tau was detected 
using HT7 monoclonal antibody, and anti-HSP70 detects endogenous levels of total heat inducible 70kDa protein HSPs. 
Expression level of Tau was normalized to actin. 
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Hsp90 inhibitors simultaneously stimulate degradation of misfolded client proteins and increase the 
expression levels of several Hsps, so the levels of hTauP301L aggregation are supposedly inversely 
correlated with Hsp70 expression. However, we did not see alteration in Hsp70 levels with the used of 
Hsp70 antibody, which was expected, in the presence of different concentrations of the compound.  
Taking into account the data shown, we can conclude that 3 µM and 10 µM 17-AAG had a clear effect on 
insoluble Tau at 48 hours after treatment. This indicates that we had a reduction in the levels of Tau 
aggregation, just in the presence of higher compound concentrations.  
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Figure 28 - Analysis of sequentially extraction of proteins from 
QBI cells stably expressing inducible TauP301L treated with 
different concentrations of 17-AAG 48 hours before the 
extraction. (A) WB analysis of QBI stable line seeded or not with 
10 µM of aggregated K18P301L with BioPORTER, and treated or 
not with 0.1 µM, 0.3 µM, 1 µM, 3 µM and 10 µM 17-AAG. 
Human total Tau was detected using HT7 monoclonal antibody, 
and anti-HSP70 detects endogenous levels of total heat inducible 
70kDa protein HSPs. Expression level of Tau was normalized by 
actin antibody. (B) Level of Tau aggregation by quantification of 
insoluble fraction band (normalized to actin), by western blot 
with HT7 antibody. N=3, average ± SD. 
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3.3. Development of assays for protein-protein interactions in living cells  
 
3.3.1. BRET assay 
 
In order to try to detect Tau-Tau interactions in living cells, we aimed to develop a BRET assay for 
monitoring transient protein-protein interactions in cells. Standard BRET system relies on the fusion of 
genetically encoded Renilla luciferase, which in presence of its bioluminogenic substrate acts as a 
resonance energy donor, and a fluorescent protein, which is a resonance energy acceptor. Currently BRET 
system emits light mostly in the green to yellow region of the visible spectrum (510-570 nm), rendering 
then suboptimal for imaging in living subjects. (Dragulescu-Andrasi, Chan, De, Massoud, & Gambhir, 2011; 
Savage, Wootten, Christopoulos, Sexton, & Furness, 2013). 
Our lab used a BRET system, with better spectral properties. This assay uses an improved luciferase 150-
fold brighter than Renilla luciferase, Nano-Luc luciferase (λem= 460nm) as donor, and HaloTag protein 
(λex/λem = 552/578nm) as the BRET acceptor. Nano-Luc is a small enzyme, of 19.1 KDa engineered for an 
optimal performance as a luminescent reporter. The luminescence reaction is ATP independent and 
designed to suppress background luminescence for maximal assay sensitivity. The HaloTag reporter 
protein is a monomeric protein, with 33 KDa, that is catalytically inactive, and it is derivative from a 
hydrolase, which forms a covalent bond with HaloTag ligands. 
BRET proteins (Nano-Luc and HaloTag) were fused with full-length Tau2N4R with P301L mutation. Four 
different combinations to test this assay were tested, combining the four constructs made. These 
combinations could be with Nano-Luc either fused to the C- or N- terminus of Tau combined with Halotag 
either fused to the C- or N- terminus of another Tau molecule (Figure 29A). The constructs for the 
different fusion proteins were verified with a BsgI digest (Figure 29B). The size of the resulting DNA bands 
corresponded to the expected pattern of 5870 and 1110 bps for Nano-Luc-TauP301L (Figure 29B, lane 2), 
6207 and 762 bps for TauP301L-Nano-Luc (Figure 29B, lane 3), 5702, 1110 and 571 bps for HaloTag-
TauP301L (Figure 29B, lane 4) and 6180, 624 and 573 bps for TauP301L-HaloTag (Figure 29B, lane 5). The 
quality of the extracted DNA was acceptable, and the constructs were verified by sequencing, which 
reveled that the clones had no mutations. It was decided to use these plasmids further to co-transfect 
cells. 
69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.1.1. Quantification of Tau-Tau interactions in QBI seeding model  
 
In order to understand if the BRET system developed by our group is functional, we made a positive 
control and a negative control with leucine zippers (LZs) constructs fused to Nano-Luc and Halo-tag 
proteins.  
LZs are particularly strong interaction domains commonly frequent in transcription factors and have been 
shown to be functional in a heterologous context (Alber, 1992; Jérôme & Müller, 2001). This three 
dimensional motif is present in proteins, functioning as a dimerization domain and its presence produces 
adhesion forces in parallel α-helices. For this reason LZs are a good positive control. 
Taking into account these characteristics, LZ was fused with C-terminal Nano-Luc and also LZ with C-
terminal HaloTag (in a similar way as the schematic representation of the Tau fusion constructs). As a 
negative control we tested the combination of LZ-HaloTag with Nano-Luc-TauP301L. The optimal BRET 
signal is generally observed with the acceptor (HaloTag) species is in a molar excess to the donor (Nano-
Luc species).  
QBI 293 cells were co-transfected with different construct ratios of 1/1, 1/10, 1/100, and 1/1000 of 
HaloTag/ Nano-Luc (combining LZ/LZ or LZ/Tau) 48 hours before adding HaloTag TMR ligand. Upon 
 B A 
I 
NanoLucTauP301LNH2
HaloTag TauP301L COOH
II 
HaloTagTauP301LNH2
NanoLuc TauP301L COOH
III 
HaloTag TauP301L COOH
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IV 
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Figure 29 - Cloning of expression plasmids for different fusion proteins of Tau Nano-Luc or HaloTag. cDNA for Nano-Luc 
TM  
luciferase or HaloTag® reporter protein was fused to the N- or C-terminus of the TauP301L. (A) Combinations: (I) HaloTag 
fused to the N-terminus of Tau and Nano-Luc fused to the C-terminus of Tau. (II) HaloTag fused to the C-terminus of Tau 
and Nano-Luc fused to the N-terminus of Tau (III) HaloTag fused to the N-terminus of Tau and Nano-Luc fused to the N-
terminus of Tau. (IV) HaloTag fused to the C-terminus of Tau and Nano-Luc fused to the C-terminus of Tau. (B) BsgI control 
digestion of plasmid pcDNA4-TO MAPT-2N4R encoding Tau-Nano-Luc and -HaloTag fusion constructs. Samples were 
digested and run on a 2% e-gel. Lane 1 shows the Smart Ladder. Lane 2 show digested Nano-Luc-TauP301L. Lane 3 show 
digested TauP301L-Nano-Luc. Lane 4 show digested HaloTag-TauP301L. Lane 5 show digested TauP301L-HaloTag.  
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Figure 30 – BRET ratios measured in QBI cell cultures co-transfected with Leucine Zipper fused to Nano-Luc and HaloTag. 
Ratio was calculated with the signal of the positive control (LZs+LZs) over the negative control (LZs+Tau). 1/1, 1/10, 1/100 and 
1/1000 corresponds to relative amounts of the plasmids co-transfected different dilutions, with acceptor species (HaloTag) in 
molar excess to the donor species (Nano-Luc).  
addition of NanoGlo (Nano-Luc substrate) luminescence was measured with band-pass filter 450 nm and 
with long pass filter 585 nm. To calculate BRET ratio this formula was used (see section 2.10 for more 
information):  
 
 
 
With LZ combination of constructs we observed a robust signal (Figure 30). The LZ-Tau combination 
resulted in no BRET signal (data not shown). We can conclude that BRET assay technically is working well, 
and that it can be used to detect interactions between proteins  
 
 
 
 
 
 
 
 
 
 
Taking into account the previous results obtained with LZ constructs, different TauP301L-fusion constructs 
combinations were tested to determine the optimal ratio of energy donor to energy acceptor, in order to 
use the best one to measure the quantity of Tau aggregation in QBI seeding model.  
For this, QBI cells were co-transfected with different constructs ratios 1/10, 1/30, and 1/100 of 
HaloTag/Nano-Luc fused to Tau2N4R-P301L (as described in topic 3.3.1). Cells were seeded with pre-
aggregated fibrils 2 days after platting. The addition of HaloTag TMR ligand was done in the day after the 
cells were seeded with fibrils and in the day of measurement, NanoGlo substrate was added to the cells. 
The luminescence was measured with a band-pass filter of 450 nm and with a long pass filter of 585 nm. 
To calculate BRET ratio this formula was used (see section 2.10 for more information):   
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We could not obtain BRET signal in any construct combination tested, since as to considered BRET signal 
the ratio must be higher than 1 (Figure 31). It was expected that in this assay the more Tau protein is 
aggregating, the higher the BRET signal will be. The signal was slightly higher with N-terminal Nano-Luc 
with C-terminal HaloTag compared to others construct combinations, but this increase was not significant 
(Figure 31-IV). The results shown in Figure 31 are an average between the experiments performed. It was 
difficult to avoid variability of levels between cells and experiments, since in this kind of assay there is 
clear difference from plate to plate. In experiments with other constructs combinations, we could not 
detect any significant BRET signal under any conditions (different dilutions).  
In order to discard the hypothesis that the problem of a lack of functioning of BRET assay is due to a lack 
of interaction between the fusion proteins, we tested the efficiency of aggregation of the different fusion 
proteins in QBI cells. For these a western blot analysis was performed on QBI cells expressing the different 
constructs and seeded with fibrils. HT7 antibody and a monoclonal Halo-tag antibody were used to detect 
the proteins in the blots. The fusion of donor and acceptor proteins with Tau did not lead to a significant 
change in aggregation kinetics in QBI seeding model, which was noticed by the absence of alteration in 
the intensity of bands present in insoluble fraction (data not shown). 
Taking into account this data, we can conclude that with these constructs combinations, it is not possible 
to measure Tau aggregation in living cells. It may however be that the position of the donor relatively to 
the acceptor and the type of linker used has a crucial relevance for this assay. With a proper optimization 
of these aspects this technique could be a promising assay to use in the future. 
 
 
 
 
 
 
 
 
 
Figure 31 –Average of BRET ratios measured in QBI cell cultures transfected with different donor and acceptor combinations. 
QBI 293 cells were co-transfected with donor species - Nano-Luc fused to the N- or C-terminus of Tau2N4R-P301L isoform and 
with acceptor species - HaloTag also fused to the N- or C--terminus of Tau2N4R-P301L isoform. 1/10, 1/30, 1/100 corresponds 
to relative quantities of the transfected plasmids, with acceptor species (HaloTag) in molar excess to the donor species (Nano-
Luc). QBI cells were also seeded or not with 10 µM pre-aggregated K18P301L (delivered to the cells with BioPORTER reagent). 
(I) Nano-Luc-TauP301L co-transfected with HaloTag-TauP301L. Average of 2 experiments is represented. (II) TauP301L-Nano-
Luc co-transfected with TauP301L-HaloTag. Average of 4 experiments is depicted. (III) TauP301L-Nano-Luc co-transfected with 
HaloTag-TauP301L. Average of 3 experiments is presented. (IV) Nano-Luc-TauP301L co-transfected with TauP301L-HaloTag. 
Average of 4 experiments is presented. Error bars ± SD. 
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3.3.2. Venus split complementation assay  
 
3.3.2.1. Qualitative analysis of Tau aggregation process in QBI seeding model 
 
As an alternative to the BRET assay to measure aggregated Tau in living cells, we developed a split GFP 
complementation-based assay using QBI seeding model. This assay had been introduced to detect the 
aggregation state of proteins in vitro, consisting on the reassembly of a fluorescent protein from its two 
complementary nonfluorescencent fragments, where its association facilitated by interaction between 
two proteins fused to each fragment (Michnick, Ear, Manderson, Remy, & Stefan, 2007; Ohashi, Kiuchi, 
Shoji, Sampei, & Mizuno, 2012) [Figure 32]. 
 
 
 
 
Our lab used a modified form of this assay with a Venus fused protein that is an improved in efficiency of 
yellow fluorescence protein. This protein contains a mutation that at 37°C greatly accelerates oxidation of 
the chromophore, the rate-limiting step of maturation (Cabantous, Terwilliger, & Waldo, 2005).  
To examine qualitatively Tau aggregation in QBI seeding model, first, three different construct 
combinations were made. N- or C-terminal part of Venus was fused to the N- or C-terminus of full-length 
TauP301L (Figure 33A). QBI cells were co-transfected with different constructs that we made, and in the 
following day the cells were seeded or not with 10 µM pre-aggregated K18P301L fibrils delivered to the 
cell by BioPORTER reagent. We observed (Figure 33BII) a fluorescent signal in even the absence of 
K18P301L fibrils. It should be noted that no fluorescence signal was observed by co-expression of the 
Venus fragments by themselves which means that there was no spontaneous association between the N- 
and C-terminal parts of Venus (data not shown). A fluorescence signal was also observed (Figure 33BII) in 
presence of K18P301L fibrils there was however a redistribution of the localization of the signal in cells 
treated with pre-aggregating seeds. 
Taking into account these data, they high background fluorescence in the absence of aggregation greatly 
reduced the usefulness of this assay. 
Figure 32- Schematic representation of Venus split 
complementation assay. Non-fluorescence fragments YN and 
YC are fused with two proteins (A and B). The interaction 
between proteins allows formation of a complex (Kerppola, 
2008).  
73 
 
 
 
 
In order to understand if the fluorescence signal obtained in the Figure above corresponds to spontaneous 
Tau aggregation in the QBI seeding model we made a constructs of Venus protein fused to Tau with two 
isoleucine to proline mutations in the MT-binding region. This mutation leads to an inefficiency of Tau 
aggregation, because proline interrupts the extended chain conformation necessary for ß-sheet 
interactions (von Bergen et al., 2001) . 
N- or C- terminal part of Venus was fused with either the C- or N- terminus of K18/P301L/2P. We tested 
different combinations of constructs in the seeded the cells with pre-aggregated K18P301L fibrils 
delivered to the cell by BioPORTER reagent (Figure 34A). The double proline mutations did not reduce the 
basal fluorescent signal suggesting that this mutation did not block the interaction between these fusion 
proteins (Figure 34BI). However, the double proline did prevent the redistribution of the florescent signal 
(Figure 34BII). This suggests that the prolines interfered with aggregation in this model. The nature of the 
interaction between the fusion proteins in the absence of aggregation induction is not entirely clear from 
this data. 
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Figure 33 - Combinations of the N- or C-terminal part of Venus fused to the N- or C-terminus of TauP301L. The N- or C-
terminal part of the Venus protein, a variant of yellow florescent protein, was fused to the N- or C-terminus of TauP301L. (A) 
Combinations: (I) N-terminal fragment of Venus fused to the C-terminus of TauP301L co-transfected with the C-terminal 
fragment of Venus fused to the N-terminus of TauP301L; (II) C-terminal fragment of Venus fused to the N-terminus of TauP301L 
co-transfected with the C-terminal fragment of Venus fused to the N-terminus of TauP301L; (III) N-terminal fragment of Venus 
fused to the C-terminus of TauP301L co-transfected with the N-terminal fragment of Venus fused to the C-terminus of 
TauP301L. (B) Fluorescence micrographs of QBI 293 cells expressing N-terminal fragment of Venus fused to the C-terminus of 
TauP301L co-transfected with the C-terminal fragment of Venus fused to the N-terminus of TauP301L; (I) not seeded with in 
vitro pre-aggregated K18P301L; and (II) seeded with in vitro pre-aggregated K18P301L. Images were acquired by a fluorescence 
microscopy with magnification of 20x. Scale bar: 450µM  
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To further study the nature of the interaction between the Tau-Venus fusion proteins in the absence of 
aggregation, constructs were made containing just MT-binding repeats. N- or C-terminus parts of Venus 
were fused to the N- or C-terminus of K18-P301L. Different combinations of constructs were co-
transfected in QBI cells (Figure 35A). One day after transfection cells were seeded with or without pre-
aggregated K18P301L fibrils delivered to the cells by BioPORTER reagent. Results obtained by fluorescence 
microscopy are shown in Figure 35B.  
All the combinations of co-transfected K18P301L-Venus constructs showed a basal fluorescent signal 
similar to the signal obtained with full length TauP301L-Venus fusion proteins (Figure 35B). This suggests 
that also K18 fusion proteins showed spontaneous interactions. In addition, some cells showed a 
redistribution of the florescent signal reminiscent as described above even in cells not seeded with Tau 
fibrils (Figure 35BI, III). The signal redistribution is greatly enhanced after seeding with K18P301L fibrils to 
levels far greater than observed with full length Tau fusion protein (Figure 35BII, IV). This could be due to 
the stronger aggregation tendency of these shorter Tau fragments.  
Analyzing the presented results, we can conclude that spontaneous aggregation in QBI seeding model 
occurs when they were co-transfected with these constructs, shown by the data obtained where we 
verified the presence of redistribution of signal in QBI cells none treated with pre-aggregated seeds. This 
means that truncated form K18-P301L increased the propensity to Tau aggregate in QBI cells.  
Taking account the results previously showed in Figure 33B and the results of the Figure 35B we can 
observed that the percentage of QBI cells with spontaneous re-distribution of signal was significantly 
Figure 34 - Combinations of double proline Tau mutant construct with Venus expression constructs. Both of Venus constructs 
are fused with proline mutated constructs of Tau contains Iso-to-Pro substitution mutations at Iso277 and Iso308 in the 
hexapeptide motifs. All of the constructs were cloned in E.coli cells. A) Combinations: N-terminal fragment of Venus fused to C-
terminus of K18/P301L/2P co-transfected with C-terminal fragment of Venus fused to the N-terminus of K18/P301L/2P; N-
terminal fragment of Venus fused to C-terminus of K18/P301L/2P co-transfected with N-terminal fragment of Venus fused to 
the C-terminus of K18/P301L/2P; C-terminal fragment of Venus fused to N-terminus of K18/P301L/2P co-transfected with C-
terminal fragment of Venus fused to the N-terminus of K18/P301L/2P. (B) Fluorescence micrographs of QBI 293 cells expressing 
N-terminal fragment of Venus fused to the C-terminus of K18/P301L/2P co-transfected with the C-terminal fragment of Venus 
fused to the N-terminus of K18/P301L/2P (I) not seeded with in vitro pre-aggregated K18P301L; and (II) seeded with in vitro 
pre-aggregated K18P301L. Images were acquired by a fluorescence microscopy with magnification of 20x. Scale bar: 450µM  
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higher for cells co-transfected with K18-P301L compared with cells co-transfected with full-length form of 
Tau. We can also conclude that spontaneous re-distribution of signal in presence or absent of fibril 
treatment was blocked with double-proline mutation. 
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Figure 35 - Combinations of K18-P301L Tau mutant constructs with Venus expression constructs. Both constructs are fused 
with K18P301L truncated form of Tau containing only the four MT-binding repeats. All of the constructs were cloned in E.coli 
cells. (A) Combinations: N-terminal fragment of Venus fused to C-terminus of K18-P301L co-transfected with C-terminal 
fragment of Venus fused to the N-terminus of K18-P301L; N-terminal fragment of Venus fused to C-terminus of K18-P301L co-
transfected with N-terminal fragment of Venus fused to the C-terminus of K18-P301L; C-terminal fragment of Venus fused to 
N-terminus of K18-P301L co-transfected with C-terminal fragment of Venus fused to the N-terminus of K18-P301L. (B) 
Fluorescence micrographs of QBI 293 cells expressing N-terminal fragment of Venus fused to the C-terminus of K18P301L co-
transfected with the C-terminal fragment of Venus fused to the N-terminus of K18P301L (I) 24 hours of BioPORTER with 
sodium acetate treatment in QBI cells; (II) 24 hours of QBI cells seeded with BioPORTER+10 µM of in vitro pre-aggregated 
K18P301L. (III) 48 hours QBI cells treated with BioPORTER+sodium acetate; (IV) 48 hours of QBI cells seeded with 
BioPORTER+10 µM of in vitro pre-aggregated K18P301L. Images were acquired by a fluorescence microscopy with 
magnification of 20x. Scale bar: 450µM  
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Abnormal phosphorylation and mislocalization of Tau is considered an early hallmark of Tauopathies such 
as AD and precedes the aggregation process present in this kind of disease. However, the role of these 
changes in pathological conditions is still poorly understood. In an attempt to make advancements in 
understanding this, it is necessary to have a fast, flexible and robust test system. The first goal of the 
experimental work shown here was to optimize a consistent in vitro model of Tauopathy, in QBI cells and 
cortical primary rat neurons. During the years, there have been many significant efforts to produce cell-
based models to mimic Tau aggregation, in a similar way to what is observed in Tauopathies, but without 
much success. One of the major obstacles is the high solubility of Tau and the fact that in solution it 
adopts a natively unfolded structure, which makes it difficult to reproduce aggregated structures in 
culture.  
The model developed by Guo and Lee and adopted by our lab could be a promising model to mimic 
aggregation process in neuronal cells (Guo & Lee, 2011). Through the use of in vitro pre-aggregated 
fibrillized material, it was possible to accelerate the intracellular fibrillization of monomeric Tau, moving 
the process from the initial lag phase to elongation phase, since the fibrils assembly occurs by a 
nucleation-dependent mechanism which corresponds to a longer step (Guo & Lee, 2011). In concordance 
with the already described seeding model in QBI cells (Guo & Lee, 2011; Master thesis Sara Calafate 2012) 
a similar model was developed in cortical neurons. Also in these cells intracellular hTauP301L aggregation 
was nucleated through seeded with in vitro pre-aggregated fibrils. In these primary cortical neuronal 
cultures no spontaneous aggregation was observed. This means that the nucleation step is a fundamental 
step in the aggregation mechanism. The same conclusion was obtained with α-synuclein in SH-SY5Y cells, 
in which aggregation could be blocked with the use of small molecular compounds that inhibits ß-sheet 
formation (Nonaka et al., 2010).  
During the optimization of the hTauP301L neuronal aggregation model, it was found that in cortical 
primary neurons it is possible to induce Tau aggregation by the simple addition of synthetic pre-
aggregated fibrils to the neuronal cultures, without the presence of any delivery reagent. This is in 
contrast to what was described (Guo & Lee, 2011) and confirmed by our group in the QBI seeding model. 
When synthetic fibrils are applied directly to the medium of the QBI cells, intracellular Tau aggregation 
was induced in only a very small percentage of cells. This suggests that in neurons, the uptake of fibrillar 
Tau and seeding of normal Tau into pathological aggregates is much more efficient that in QBI cells. The 
uptake of in vitro pre-aggregated Tau fibrils has been shown to be regulated by non-receptor mediated 
endocytosis (Frost, Jacks, et al., 2009; Wu et al., 2013). Wu et al. suggested that in HeLa cells the 
internalized aggregates are transported via endosomal vesicles and trafficked through the endosomal 
pathway to lysosomes (Wu et al., 2013). This process can also occur in QBI cells, and without the presence 
of the BioPORTER delivery reagent, the cells can internalize a small quantity of aggregates in the same way 
that occurs in neurons. However, these aggregates can be forwarded to lysosomes and be immediately 
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degraded by autophagy-lyssomal system. If this occurs, there is no possible induction of aggregation by 
synthetic pre-aggregated fibrils in QBI cells without a delivery reagent. The use of the delivery reagent 
may increase the quantity of aggregated material taken up by the QBI cells, or it may alter the pathway by 
which the fibrils are taken up by the cells, which may protect the seeds from degradation. 
It was observed in the hTauP301L neuronal model that the amount of hTauP301L aggregation is 
dependent on the amount of Tau mutant fibrils added to the system. This strongly suggests that an 
increase in uptake of in vitro pre-aggregated fibrils will trigger a higher level of intracellular hTauP301L 
aggregation. Eisenberg and Jucker demonstrated that if the transition of limitant step is exceeded, a 
higher concentration of the fibrils leads to an increase in aggregation (Eisenberg & Jucker, 2012). This data 
is also supported by the fact of Tau having amyloid fibril structure, and fibrils seeds are rich in cross-β-
sheet secondary structure, that will facilitate aggregation of other proteins with this kind of structure (Lee, 
Lim, Masliah, & Lee, 2011).  
During the optimization of the hTauP301L neuronal aggregation model it was not possible to demonstrate 
that recombinant K18P301L fibrils could induce WT Tau aggregation in cellular and neuronal systems. In 
cells transduced with hTauWT, a monomeric protein was detected in the total fraction similar to what was 
observed with cells transduced with hTauP301L. However, no WT Tau was found in the insoluble fraction 
after seeding the cells with fibrils. In addition, no increase in staining with AT8, a phospho-specific 
antibody, was seen after fibril seeding as was observed with TauP301L expressing neurons. This evidence 
is consistent with events that occur in FTDP-17 patients with the P301L mutation, since they do not 
present insoluble WT Tau deposition (Miyasaka et al., 2001). However it may be that WT does aggregate 
in this model, albeit at a much slower rate than Tau with the P301L mutation, a mutation that leads to an 
increased fibrilization propensity (Guo & Lee, 2011; Waxman & Giasson, 2011). In an attempt to verify this 
possibility, an experimental procedure to study the aggregation dynamic of hTauWT could be done, 
increasing the days of exposure to synthetic pre-aggregated fibrils in cultures expressing endogenous WT 
Tau. On the other hand, we could also study the aggregation process in cultures exposed to synthetic WT 
fibrils and expressing endogenous WT Tau.  
One of the characteristics that has been associated with the Tau pathology in recent years is a temporal 
and spatial spread of NFT through the brain (Braak & Braak, 1991; Clavaguera et al., 2009). We observed 
that in vitro pre-aggregated fibrils induced hTauP301L aggregation in a time dependent manner. It was 
observed that an increase in neuronal exposure length to pre-aggregated synthetic fibrils resulted in an 
increase in detection of hTauP301L aggregation. With an increase in exposure time to fibrillar material, a 
small increase in Tau aggregation, detected with HT7 antibody, was observed. The pre-tangle material, a 
soluble Tau form, can be identified by the AT8 antibody. However, the most imuno-reactivity achieved 
with this antibody is with the low migrating fraction/insoluble fraction as that this antibody is specific to 
phosphorylated epitopes Ser202 and Tyr205 (Augustinack et al., 2002; Braak & Del Tredici, 2011). So, with 
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this data we could not confirm an increase in phosphorylated Tau over time. However, it was possible to 
detect an increase in aggregated hTauP301L over time, since the aggregation process showed an 
exponential growth (DIV14 and 17) until the reaction reached an equilibrium phase, where the rate of 
fibrils growth was equal that of shrinkage (DIV20 and 22). The data presented here are supported by the 
amyloid fibrillation process (Lee et al., 2011). A hypothesis that could explain the increase in hTauP301L 
aggregation is the constitutively expression of transduction protein over time, in presence of synthetic 
fibrils. This may mean that a change in conformation of soluble Tau occurs induced by fibrillar material. 
However, it is not possible to determine the existence of spreading in these experimental procedures. This 
is because it is not noticeable in these kinds of neuronal cultures if the aggregated Tau spreading is from 
one cell to another or if each neuron uptakes the pre-aggregated fibrils. In order to overcome this 
problem and investigate if there is a spreading mechanism associated with the hTauP301L aggregation, 
microfluidic polydimethylsiloxane chambers could be used, since this kind of technique can allow to 
separate two chambers with different conditions, but keep dendrites and axons across both chambers, so 
the uptake and movement inside cells could be studied. 
Neurodegeneration is closely associated with a neuronal loss in AD (Braak & Braak, 1997), although the 
mechanisms of Tau-mediated cell death are still under debate (Spires-Jones, Kopeikina, Koffie, De 
Calignon, & Hyman, 2011). In our hTauP301L neuronal aggregation model we could not correlate a 
decrease in neuronal viability over time with aggregation of hTauP301L. The initial increase in quantity of 
neurons from DIV0 to DIV3 observed in data could be explained by the loss of neurons in DIV0 due to 
washing steps that must be performed during the Immunocytochemistry protocol. All cortical neurons 
may not be adhered tightly to the plate 19 hours after plating, and with the washing steps some neurons 
may be removed. In primary cortical neurons there was no detection of any difference in cell viability in 
neurons that were transduced with TauP301L and seeded with in vitro pre-aggregated fibrils, compared to 
neurons neither transduced with TauP301L nor seeded with fibrils. The decrease in neuronal viability that 
occurs is related to the neuronal death process that happens to the neurons with an increase of days in 
culture. AD patients show an activation of inflammatory cells (Wyss-Coray, 2006), in agreement with this 
neuronal cultures also show an increase in non-neuronal cells, which may correlate with an increase in 
glial cells. This means that the aggregation process triggered by P301L Tau mutation and the presence of 
synthetic fibrils is not neurotoxic in cortical neurons.  
In the P301L injected mice model developed by our group and described by Iba et al., with an intracellular 
injection of in vitro pre-aggregated fibrils (Iba et al., 2013), we detected no cell loss in the cortex. However, 
significant cell death was observed in the CA1 hipocampal region in the in vivo injection mouse model, 
observed with Nissl staining. Therefore, effects on neuronal viability in this model should be repeated 
using hippocampal cultures. With this knowledge it could be possible to have an increased bridge between 
the in vitro and the in vivo models. 
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Our study provides two models for the study of molecular mechanisms involved in Tau pathology, 
although the heterogeneity between cells (in primary cortical neurons as well in QBI cells) is obvious in all 
of the experiments performed with these models. This is however an evident problem for every attempt 
at optimizing a cellular model, since multiple mechanisms could often exist for a particular cellular 
behavior or activity. These mechanisms can also vary between individual cells, even within the same 
monoclonal population (Altschuler & Wu, 2010; Pelkmans, 2012). In a cellular model used to test 
compounds, the cell variability can be a problem as we would encounter extreme difficulties replicating 
the results, although these cellular differences may have no functional significance.  
Mechanisms to avoid variability between cells will therefore need to be performed, for example we could 
increase the number of cultures being studied at the same time, which could be done by pooling 
repetitions with same conditions. In a primary culture it is also important to factor in the existence of 
other different brain cells within the culture, since the amount of protein being measured in the 
biochemical analysis may not all be from the neurons. A possibility to avoid this is to use for example a 
compound that partially inhibits astrocyte growth. The use of “housekeeping” proteins, such as actin, 
could be another problem in experiments performed with this model. This is because actin levels are often 
chose as reference in assays with the assumption that their variation in expression is small and/or 
biologically unimportant, but this may not be the case (Altschuler & Wu, 2010). The fact that actin is also 
not present in the insoluble fraction is another problem within this model. 
Intracellular deposits of insoluble hyperphosphorylated Tau protein are one of the major pathogenic 
features associated with AD. Aberrant Tau aggregation may result in part from failure of chaperone-
mediated protein ubiquitination and degradation (Waza et al., 2006). It has been shown that molecular 
chaperones are capable of reducing phosphorylated Tau and could prevent Tau-associated cellular toxicity 
(Petrucelli et al., 2004). Hsp90 is a major cellular chaperone which is evolved in the assembly of large 
complexes with a variety of co-chaperones, and its functions are to maintain protein quality control and 
assist in protein degradation. Tau is a client protein of this Hsp90 complex, so if the protein is in an 
abnormal or modified form, there may be recruitment of the CHIP protein, a co-chaperone with E3 activity, 
to the Hsp90-Tau complex, resulting the ubiquitination of Tau protein (Petrucelli et al., 2004; Salminen et 
al., 2011). Dickey et al. observed that CHIP can distinguish between Tau proteins phosphorylated at 
normal Ser residues and Ser/Thr phosphorylated Tau sites associated with pathological form of Tau 
protein and will then only bind to the aberrant proteins. This group also demonstrated that high-affinity 
Hsp90 binding complexes are present in AD patients samples, but not in control samples (Dickey et al., 
2007). It was demonstrated that CHIP protein, in collaboration with Hsp90 complex, caused degradation 
of phosphorylated Tau. Inhibition of the Hsp90 complex promotes the selective degradation of 
phosphorylated Tau protein in vivo model of Tauopathy (Andorfer et al., 2003), indicating that the 
blockage of folding/refolding pathways promotes the degradation of phosphorylated Tau protein (Dickey, 
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Yue, et al., 2006; Dickey et al., 2007). This study demonstrates that Hsp90 inhibitors could provide a 
possible therapeutic strategy for AD, by the enhancement of Hsp90/CHIP mediated Tau phosphorylation. 
To develop a way to induce the clearance of Tau aggregates, through the use of Hsp90 inhibitors, was one 
of aims of the work shown here. Previous work already developed in our group, with 17-DMAG, an Hsp90 
inhibitor, showed that there was an active inhibition of the Hsp90 activity and a decrease in Tau 
aggregation (Master thesis Sara Calafate 2012). However, Dickey et al. showed an increased in toxicity for 
neurons treated with 17-DMAG compared to neurons treated with 17-AAG (Dickey, Dunmore, et al., 2006). 
Taking into account these conclusions, the effect of 17-AAG (Hsp90 inhibitor) was studied in the QBI 
seeding model, as well in the hTauP301L neuronal aggregation model. In the QBI seeding model it was 
detectable a decrease in Tau aggregation in cells treated with 17-AAG. This evident effect in soluble and 
insoluble aggregated Tau species, dependent on the concentration of inhibitor, clearly contradicted the 
results previously obtained by our group (Master thesis Sara Calafate 2012). However, in this model there 
was no visible activation of chaperone machinery, since the levels of Hsp70 reamined constant, not 
showing changes with treatment with Hsp90 inhibitor. This could be due to the fact that basal levels of 
Hsp70 expression in QBI cells are very high in conditions without treatment, so in case of cells treated with 
Hsp90 inhibitors there is no visible difference in the expression of Hsp70. 
In the hTauP301L neuronal aggregation model, with 17-AAG treatment, as observed in QBI seeding model, 
there was also a dose dependent decrease in soluble Tau protein and an insoluble aggregated Tau. 
However it is evident an activation of chaperone machinery after neuronal treatment with 17-AAG 
inversely correlates with an increase in levels of Hsp70, as expected (Dickey et al., 2008). However, toxicity 
tests of some Hsp90 inhibitors made in our group on the hTauP301L neuronal aggregation model 
observed that toxic effects increased over time. The effects of Hsp90 inhibitors on Tau levels also correlate 
strongly with toxicity of this compound (data not shown). This fact makes this in vitro model inappropriate 
to test the Hsp90 inhibitors. Hsp90 inhibitors were also tested in the fibril injected P301L transgenic 
mouse model, but no positive results were achieved. We have also not tested the effects on the soluble 
and insoluble fractions in animals treated with one of the Hsp90 inhibitor. This was because the toxicity of 
these compounds was found to be too high, triggering extensive damage in the rat’s organs. Taking this 
into account the Hsp90 inhibitor that showed less toxicity should be retested in a less aggressive mouse 
model of Tau aggregation. 
Natural or herbal compounds could be potential candidates for the treatment of Tauopathies, such as AD. 
Ma et al. described that curcumin, a polyphenolic compound derived from the plant Curcuma Long Lin, 
reduced levels of soluble Tau dimers but not the levels of insoluble and monomeric phosphorylated Tau. 
This compound may act by increasing the levels of Hsp70, Hsp90 and HSC70 (Ma et al., 2013; Ringman et 
al., 2012). Our preliminary results with curcumin treatment in the hTauP301L neuronal aggregation model 
showed a decrease in levels of soluble and insoluble hTauP301L in cortical neurons exposed to this 
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compound for 48 hours, however there was no detection of any alteration in Hsp70 levels (data not 
shown). The ability of this compound to decrease Tau aggregation, and the role of Hsps still needs to be 
studied with a stronger effort. 
It is necessary to try to find new strategies to increase protein turnover by, for example ubiquitin-
proteossome system or/and by autophagy (Rubinsztein, 2006) and delay or inhibiting Tau aggregation by, 
for example, inhibitors that will have been effect in ß-sheet conformation. (Zheng et al., 2011; Zheng, 
Baghkhanian, & Nowick, 2013). Methylene blue has been shown to be an inhibitor of Tau aggregation in 
vitro (Taniguchi et al., 2005; Wischik et al., 1996) and in vivo (O’Leary et al., 2010). Congdon et al. 
demonstrated that methylene blue is capable of inducing autophagy in primary cortical neurons, in 
organotypic slice cultures and transgenic animals (JNLP3). This led to a decrease in levels of 
hyperphosphorylated soluble and insoluble Tau, as well in levels of aggregated Tau (Congdon et al., 2012). 
The reduction of phosphorylated Tau aggregation was also detected in another study using P301L Tau 
transgenic mice (Hosokawa et al., 2012). However several different mechanisms of action for this 
compound have been proposed. A study from Crowe et al. demonstrated that methylene blue has an 
effect on Hsp70 by inducing of Tau dimerization and these dimmers are excluded from the aggregation 
process (Crowe et al., 2013). This potential compound is in clinical trials in phase II with promising results 
in AD patients (Crowe et al., 2013). This evidence makes this compound a potential candidate for the 
inhibition of Tau fibrillization, and a possible lead compound to develop new potential compounds to treat 
AD. 
Developing techniques to identify and analyze protein-protein interactions is extremely important to 
understanding various disease mechanisms and developing new therapeutic approaches. These 
interactions are present in many key events in cell processes, from division to adaption or response to 
extracellular signals, leading to biological effects. The establishment of an assay to quantitatively monitor 
Tau aggregate formation in living cells was one of the aims of the experimental project present here.  
BRET system has several advantages compared with others methods. Since it is a homogenous assay, it 
could be performed in live cells as a fluorescence resonance energy transfer (FRET) assay, but with much 
higher sensitivity, that will permit monitoring interactions between proteins in an intact cellular context 
(Couturier & Deprez, 2012). We developed a BRET system with better spectral properties in an attempt to 
evaluate the Tau aggregation process in the QBI seeding model. To perform this technique, Nano-luc 
luciferase was used as a donor with the HaloTag protein, an affinity tag that can be covalently bound to 
molecules, being used as an acceptor. Our data with LZs indicates the maximal BRET signal that we could 
obtain in an optimal situation. This is because these structures work as a dimerization domain with their 
presence producing adhesion forces in parallel α-helices (Jérôme & Müller, 2001) which lead to an 
increased in proximity of constructs and an efficient transference of energy between donor and acceptor 
species. Building on the data obtained, this BRET system could be a promising assay to detect the 
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interaction between Tau proteins, in order to detect aggregation. The obtained signal from the BRET 
constructs fused with full-length Tau was expected to have a lower signal than the positive control, with 
LZ. The signal obtained from full-length Tau was indeed lower, but it was too low to be considered as a 
positive BRET signal, as to be considered BRET signal, the ratio must be above 1. Considering this, we 
could conclude that it is not possible to detect BRET signal with constructs using full-length form of Tau. 
This can be explained by the natively unfolded structure and a low content of secondary structure present 
in full-length form of Tau protein. These properties result in the presence of high fraction of basic 
hydrophilic amino acid residues, which resist the compact folding typical of most proteins (Jeganathan, 
Von Bergen, Mandelkow, & Mandelkow, 2008; Mukrasch et al., 2009). As such, these properties of Tau 
mean the constructs are not able to interact and transfer energy efficiently, even in presence of in vitro 
pre-aggregated fibrils to induce aggregation. Changing full-length TauP301L by Tau K18-P301L construct to 
fuse with Nano-Luc and HaloTag could be an hypothesis to better study this, since K18-P301L constructs 
have the same ß-structure of the full-length form of TauP301L but are a smaller size, just 129 aa, 
compared to the 441 aa of full length Tau (Jeganathan et al., 2008). This construct has a which could lead 
to a higher capacity of interaction and efficient energy transfer, and as a consequence, the detection of 
BRET signal. 
As an alternative to BRET assay, to monitor Tau aggregate formation and evaluate how the process is 
modulated in living cells (Cabantous et al., 2005), we developed a variant of split GFP complementation 
assay, with Venus instead of GFP protein. This assay is extremely advantageous, especially due to its ease 
of use, and by the high sensitivity of the detection system (Kerppola, 2008; Pusch, Dissmeyer, & Schnittger, 
2011). This relies on the fusion of two non-fluorescent halves of the functional Venus with the protein of 
interest, in our case Tau protein. In the study presented here, split Venus complementation with different 
Tau constructs was investigated in the QBI seeding model. Therefore full-length TauP301L exhibited 
complementation between the two halves of Venus, in the absence or presence of Tau aggregation 
induction, although the aggregation-resistant proline mutant also showed a fluorescence signal, but 
without signal re-distribution on cells. Nevertheless, the aggregation prone mutation, K18P301L, exhibited 
complementation efficiency with synthetic pre-aggregated fibrils treatment. However, there appears to 
be some complementation of the two halves of Venus without treatment with in vitro pre-aggregated 
fibrils that corresponds to a spontaneous Tau-Tau binding. This could be due to the formation of a dimeric 
complex of Tau. In order to exclude the possibility of a higher Venus complementation detection due to 
the proximity of Tau proteins which are bound to microtubules, QBI cells could be treated with a 
microtubule destabilizer, for example Nocodazole, to disrupt MT cytoskeleton and leave Tau unbound 
(Celik, Abdulreda, Maiguel, Li, & Moy, 2013). Venus halves could also be fused with full-length Tau with 
cysteine residues mutated, since these residues are essential for Tau assembly to the microtubules 
(Walker, Ullman, & Stultz, 2012). 
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Other methods to monitor protein misfolding/aggregation in living cells are in development and could be 
used in the future to detect Tau-Tau interactions The aggregation process could be monitored by assays 
using fluorescence reporter proteins, as folding reporter GFP fused to the C-terminus of a target protein, 
and the fluorescence intensity of cells expressing this reporter protein is directly proportional to correct 
folding of target protein (Waldo, Standish, Berendzen, & Terwilliger, 1999). Another assay using 
fluorescence reporter proteins is a FRET, in this assay the N- and C-termini of the target protein is tagged 
with each of the fluorescence proteins and the folding status could be determined by the FRET signal from 
the two proteins (Philipps, Hennecke, & Glockshuber, 2003). It is also possible to monitor protein 
aggregation using enzymatic activity assays, as complementation of split enzyme reporters, wherein two 
fragments that are fused to the N- or C- termini of the target protein will not be able to self-assemble, 
leading to a reduction of enzymatic activity, an example of this assay is a complementation with ß-
galactosidase (Wigley, Stidham, Smith, Hunt, & Thomas, 2001). 
 
 
 
Concluding Remarks 
 
The search for an explanation for the pathology mediated by Tau and how alterations in this protein can 
trigger toxicity in the brain remains a major question for the scientific community. This present study 
provides two robust in vitro models, to study molecular mechanisms involved in Tau related pathology. 
The neuronal aggregation model has an advantage over the in vivo model due to the faster data 
generation and the easier manipulation. It is also better than the QBI seeding model due to the larger 
similarities with pathways that exist in the brain. Both models are however a strong and robust cellular 
system of Tau aggregation, showing key features of Tau associated disorders, and with an advantageous 
number of applications. 
 
Our cellular Tauopathy models provide an invaluable platform to try to identify pathways involved in 
aggregation and in clearance of Tau aggregates, as well as new compound candidates. This could be 
applied, for example, in compound screening that prevents or delays Tau aggregation, to identify new 
targets by individual gene manipulation (over-expression or knocking-down). Lastly this could be used to 
validate targets and pathways already described with compounds and targets identified in other diseases 
related with aggregation or in diseases with similar pathways. 
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